



**Impact of comorbidity on risk of venous thromboembolism
in breast cancer patients – A Danish population-based
cohort study.**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005082
Article Type:	Research
Date Submitted by the Author:	18-Feb-2014
Complete List of Authors:	Ording, Anne; Aarhus University Hospital, Department of clinical Epidemiology Horváth-Puhó, Erzsébet; Aarhus university Hospital, Department of Clinical Epidemiology Garne, Jens Peter; Aalborg University Hospital, Breast Clinic Nyström, Petra; Uppsala University Hospital, Department of Oncology Vyberg, Mogens; Aalborg University Hospital, Institute of Pathology Toft Sørensen, Henrik; Aarhus university Hospital, Department of Clinical Epidemiology; Aarhus University Hospital, Department of Clinical Epidemiology Lash, Timothy; Emory University, Department of Epidemiology; Aarhus university Hospital, Department of Clinical Epidemiology
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Haematology (incl blood transfusion), Epidemiology
Keywords:	EPIDEMIOLOGY, ONCOLOGY, Bleeding disorders & coagulopathies < HAEMATOLOGY

SCHOLARONE™
Manuscripts

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1, 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5, 6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5, 6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	5, 6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6
Bias	9	Describe any efforts to address potential sources of bias	6, 7
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7, 8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7, 8
		(b) Describe any methods used to examine subgroups and interactions	7, 8
		(c) Explain how missing data were addressed	7, 8
		(d) If applicable, explain how loss to follow-up was addressed	N/A
		(e) Describe any sensitivity analyses	N/A
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	12, 13
		(c) Summarise follow-up time (eg, average and total amount)	14
Outcome data	15*	Report numbers of outcome events or summary measures over time	14
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	14
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	10
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10, 11
Generalisability	21	Discuss the generalisability (external validity) of the study results	11
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16, 17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1
2
3
4 **Title: Impact of comorbidity on risk of venous thromboembolism in breast cancer patients – A Danish**
5
6 **population-based cohort study**
7
8
9

10 **Authors and affiliations**

11 Anne Gulbech Ording¹

12 Erzsébet Horváth-Puhó¹

13 Jens Peter Garne²

14 Petra Witt Nyström³

15 Mogens Vyberg⁴

16 Henrik Toft Sørensen¹

17 Timothy L. Lash^{1,5}

18 ¹Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

19 ²Breast Clinic, Aalborg University Hospital, Aalborg, Denmark

20 ³Department of Oncology, Uppsala University Hospital, Uppsala, Sweden

21 ⁴Institute of Pathology, Aalborg University Hospital, Aalborg, Denmark

22 ⁵Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA

23
24
25
26
27
28
29
30
31
32 **Corresponding author**

33 Anne G. Ording, Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200

34 Aarhus N. E-mail address: ao@dce.au.dk; Telephone: +45 87 16 80 63; Fax: +45 87 16 72 15

35
36
37
38
39
40
41
42
43
44
45
46
47
48 **Running title:** Breast cancer, comorbidity and risk of VTE

49
50
51 **Key words:** Breast neoplasms, comorbidity, morbidity, venous thrombosis, haemostasis, epidemiology

52
53
54 **Abstract word count: 218, manuscript word count: 2,156.**
55
56
57
58
59
60

Abstract

Objectives: To assess the interaction between comorbidity and breast cancer (BC) on the rate of venous thromboembolism (VTE) beyond what can be explained by the independent effects of BC and comorbidity.

Design: Population-based matched cohort study.

Setting: Denmark.

Participants: Danish BC patients (n=62,376) diagnosed 1995–2010 and a comparison cohort of women without BC (n=304,803) from the general population matched to the BC patients on year of birth in five-year intervals and on the specific diseases included in the Charlson Comorbidity Index (CCI) and atrial fibrillation and obesity.

Measures: The rate ratios of VTE per 1000 person-years (PYs) were computed by comorbidity levels using the CCI, and interaction contrast were calculated as a measure of the excess or deficit VTE rate not explained by the independent effects of BC and comorbidity.

Results: Among BC patients with a CCI score of 1, the 0-1 year VTE rate was 12 per 1000 person-years (PYs), and interaction accounted for 10% of the rate (IC= 3.2, 95% confidence interval (CI), 0.5, 5.9). Among BC patients with CCI ≥ 4 , the VTE rate was 17, and interaction accounted for 8% of the rate (IC= 1.2, 95%CI, -1.8, 4.2). There was no interaction during ≥ 1 -5 years of follow-up.

Conclusion: There was only little interaction between BC and the CCI score on the rate of VTE.

Article summary

- The study included all Danish breast cancer patients diagnosed 1995–2010 and a comparison cohort of women from the general population free of breast cancer. The study had complete follow-up on all participants from the nationwide Danish Civil Registration System.
- The study was conducted in a government financed health care system with equal access for the entire Danish population.
- The validity of the Danish National Registry of Patients as a source of information on comorbidity and VTE has varying completeness and validity for different diseases.
- The CCI as a measure of the combined burden of comorbidity does not allow for estimation of disease severity and duration.

Background

Venous thromboembolism (VTE), i.e., deep venous thrombosis (DVT) and pulmonary embolism (PE), is associated with high morbidity and mortality, in particular during hospitalization.[1] Cancer and VTE are strongly related and VTE can be a marker of occult cancer as well as a serious complication of cancer.[2] Cancer-associated VTE risk is up to seven times higher compared to that of the general population,[3-5] and the rate is mainly increased during the first year following cancer diagnosis.[3,6]

1
2
3
4 Important risk factors include cancer type and cancer stage, but may also be related to treatment
5
6 including chemotherapy and central venous catheters used for treatment administration.[1,7,8]
7
8

9
10 Breast cancer is the most common cancer among women in most of the developed world,[9] and an
11
12 estimated 20% of patients are burdened with major comorbid conditions at diagnosis.[10] While there
13
14 is evidence for a link between some diseases, such as stroke, heart failure, and osteoporosis, and risk
15
16 of VTE,[11-14] it is largely unknown how chronic diseases in breast cancer affect the risk of VTE
17
18 compared to the general population free of breast cancer.
19
20
21

22
23 To our knowledge, no studies have compared the risk of VTE among BC patients to a comparison
24
25 cohort of women free of BC and accounted for comorbidity. We computed the interaction contrast
26
27 (IC) as a measure of interaction between breast cancer and comorbidity levels using the Charlson
28
29 Comorbidity Index (CCI) as a measure of comorbidity.[15] The IC is an estimate of the VTE rate that
30
31 cannot be explained by the effects of breast cancer or comorbidity acting alone.[16]
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods

Design and setting

To compare VTE rates in a cohort of breast cancer patients with corresponding rates in a cohort of women free of breast cancer, we designed a nationwide cohort study including all patients diagnosed with breast cancer in Denmark between 1995 and 2010 and a comparison cohort of women selected from the general population. Women in the comparison cohort were matched to each breast cancer patient on year of birth in five-year intervals and on the specific diseases included in the CCI,[15] and on history of atrial fibrillation and obesity, as atrial fibrillation is treated with anticoagulation and obesity is a risk factor for VTE.[17,18]

The study used administrative and medical registries in Denmark, where the national health care system provides tax-supported access to primary care and hospitals for all legal residents.[19] The Civil Registration System (CRS) maintains up-to-date information on vital and civil status for all Danish residents.[20] Since 1968, all residents of Denmark have been assigned a Civil Personal Registration (CPR) number, which facilitates accurate linkage between medical registries. This study made use of such registries to provide information on breast cancer and other hospital diagnoses (see appendix).[20]

Ascertainment of the breast cancer and comparison cohorts

The Danish Cancer Registry (DCR) was established in 1943 and records all cancers diagnosed in Denmark.[21,22] We identified all female breast cancer patients diagnosed between 1995 and 2010 and excluded patients with a VTE diagnosis preceding the index (diagnosis) date. For women in the

1
2
3
4 comparison cohort, the index date was defined as the date of breast cancer diagnosis for the matched
5
6
7 case.

8
9 From the CRS, we selected up to five women from the general population and matched them without
10
11 replacement to each breast cancer patient on age (5-year intervals) and on hospital history of specific
12
13 comorbidities included in the CCI,[15] and on presence/absence of atrial fibrillation and obesity.
14
15

16
17 Women in the comparison cohort could not have previous diagnostic codes for breast cancer or VTE
18
19 as of the date of breast cancer diagnosis for the corresponding case.
20
21

22 23 24 *Comorbidity*

25
26 The Danish National Registry of Patients (DNRP) contains information on all non-psychiatric discharge
27
28 diagnoses for inpatient hospitalizations since 1977. Information on visits to outpatient specialist and
29
30 emergency departments was added from 1995. The DNRP records diagnoses and dates of hospital
31
32 contacts.[23] This registry was used to identify all diagnoses of diseases included in the CCI,[15] as well
33
34 as atrial fibrillation and obesity, for members of the two cohorts (see Appendix). Atrial fibrillation and
35
36 obesity were included in the CCI with a weight of one.
37
38
39
40
41
42
43
44

45 46 *Venous thromboembolism*

47
48 The study outcome was VTE, defined as any in- or outpatient discharge diagnosis of PE, DVT, or other
49
50 VTE diagnosed after the index date (see Appendix).[24] Due to the little impact on mortality risk
51
52 associated with DVT alone, patients coded as having both DVT and PE on their first diagnosis date
53
54
55
56
57
58
59
60

1
2
3
4 were classified as PE patients.
5
6
7

8 9 *Follow-up*

10 The breast cancer and comparison cohorts were followed from the index date until the first
11
12 occurrence of VTE, death, emigration or five years of follow-up, whichever came first. If a matched
13
14 comparison cohort member received a breast cancer diagnosis, follow-up was censored and the
15
16 woman was switched to the breast cancer cohort. The person-time was divided into two survivor
17
18 cohorts, the first with one year of follow-up and the second with more than one to five years of
19
20 follow-up.
21
22
23
24
25
26
27
28
29

30 *Statistical analysis*

31
32 First, we computed proportions of women in the breast cancer cohort and the matched comparison
33
34 cohort within categories of age (0–59, 60–69, 70–79, and ≥80 years), index year (1995–1999, 2000–
35
36 2004, and 2005–2010), baseline CCI score (0, 1, 2–3, ≥4), individual CCI comorbidities,
37
38 presence/absence of atrial fibrillation and obesity, and—for the breast cancer cohort—breast cancer
39
40 stage at diagnosis (local, regional, distant, or unknown).
41
42
43
44

45 Next, the Kaplan-Meier (KM) method was used to compute crude survival and cumulative incidence
46
47 estimates for VTE accounting for the competing risk of death.[25]
48
49

50 We then computed the rate of VTE within the categories described above for the two cohorts and
51
52 created Cox proportional hazard regression models to compute the hazard ratios (HRs) adjusted for
53
54 age (continuous) and year of breast cancer diagnosis (1995–1999 vs. 2005–2010, 2000–2004 vs.
55
56
57
58
59
60

1
2
3
4 2005–2010) to compute rate ratios for VTE within strata of comorbidity. As comorbid conditions were
5
6
7 matched factors, the matching had to be dissolved in all adjusted analyses and for analyses of the >1–
8
9
10 5 year survival cohort. To account for changes in the age distribution at one year of follow-up, VTE
11
12 rates for the >1–5 year survivor cohort were standardized to the age distribution of the breast cancer
13
14 patients as of their index dates.
15

16
17
18 The interaction between breast cancer and comorbidity on the rate of VTE was examined by
19
20 calculating the IC, which measures the excess or deficit rate of VTE above or below that expected
21
22 given the baseline VTE rate, the effect of breast cancer on the VTE rate, and the effect of comorbidity
23
24 on the VTE rate.[16] It is calculated as the difference between the rate differences (VTE rate in the
25
26 breast cancer cohort minus the VTE rate in the comparison cohort) in the strata with and without
27
28 comorbidity.[16]
29

30
31
32
33 Analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, NC).
34

35
36 The study was approved by the Danish Data Protection Agency (2011-41-6174).
37

38 39 40 **Results**

41
42
43 Descriptive statistics of the cohorts are shown in Table 1. The study included 62,376 breast cancer
44
45 patients and 304,803 women from the general population matched to the breast cancer patients
46
47 diagnosed between 1995 and 2010. The median age in the breast cancer cohort was 62.3 years
48
49 (inter-quartile range, 52.8, 72.3), and 75% of the cohort members had a CCI score of 0 at the time of
50
51 breast cancer diagnosis. During the first year of follow-up, there were 502 and 668 cases of VTE in the
52
53 breast cancer and the matched comparison cohort, respectively, of which 39% vs. 46% were DVT, 35%
54
55
56
57
58
59
60

1
2
3
4 were PE in both cohorts, and 26% vs. 19% were other VTEs, respectively. By five years of follow-up, an
5
6 additional 789 cases of VTE were diagnosed in the breast cancer cohort and 2,308 in the comparison
7
8 cohort.
9
10

11
12 Table 2 presents the VTE rates, ICs, and adjusted VTE rate ratios for 0–1 year and >1–5 years of
13
14 follow-up in the breast cancer and comparison cohorts. After taking into account death as a
15
16 competing risk, the breast cancer cohort was at higher risk for all types of VTE within 1 year and at 5
17
18 years of follow-up. At one year of follow-up, the VTE rate was 8.4 (95% confidence interval (CI), 7.7,
19
20 9.2) per 1000 person-years (PY) in the breast cancer cohort and 2.2 (95% CI, 2.1, 2.4) per 1000 PY in
21
22 the comparison cohort (data not shown). In all strata of CCI scores, the breast cancer cohort had
23
24 higher rates of VTE compared to the comparison cohort, but the corresponding hazard ratios (HRs)
25
26 decreased with increasing CCI score. The HR for VTE was 4.8 (95%CI, 4.1, 5.6) for a CCI score of 0, and
27
28 1.3 (95%CI, 0.7, 2.4) for a CCI score of ≥ 4 . During ≥ 1 –5 years of follow-up, the corresponding HRs
29
30 were 2.2 (95%CI, 2.0, 2.4) for a CCI score of 0 and 1.5 (95%CI, 0.9, 2.5) for a CCI score of ≥ 4 .
31
32
33
34
35
36
37
38

39 The IC analysis revealed a small amount of interaction between breast cancer and the CCI score,
40
41 which weakened with increasing CCI score, suggesting that the combined effect of breast cancer and
42
43 comorbidity mainly impacts the VTE rates in presence of low comorbidity levels. Interaction
44
45 accounted for 3.2 (95%CI, 0.5, 5.9) cases of VTE per 1000 PY for a CCI score of 1, 1.2 (95%CI, –1.8, 4.2)
46
47 cases of VTE for a CCI score of 2–3, and –1.3 (95%CI, –11, 7.9) cases of VTE for a CCI score of ≥ 4 per
48
49 1000 PY, representing 27%, 10%, and –7.6% of total VTE rates, respectively. During >1–5 years of
50
51 follow-up weak interaction was only observed for a CCI score of ≥ 4 (IC, 2.3, 95%CI, –4.3, 8.9/1000PY),
52
53 corresponding to 23% of the total VTE rate.
54
55
56
57
58
59
60

Discussion

In this nationwide study, the breast cancer cohort had elevated rates of VTE compared to women from the comparison cohort in all categories of comorbidity. However, comparing the breast cancer cohort to the comparison cohort within levels of the CCI score, VTE rate differences remained nearly constant as the comorbidity level increased, whereas the rate ratios declined with increasing CCI score. We found that there was only a small amount of interaction between breast cancer and the CCI score on the VTE rate, which primarily was observed during the first year after breast cancer diagnosis for patients with a CCI score of 1. This pattern of effects and interactions suggests that comorbidity and breast cancer or its treatment effect the rate of VTE for breast cancer patients with a CCI score of 1 and in the first year of follow-up. In women with multiple comorbidities, and at longer times of follow-up, the independent effects of comorbidity, breast cancer, and its treatments dominate the overall risk of VTE, possibly due to the higher baseline risk of VTE contributed by each of these factors.

In our study, breast cancer patients had higher VTE rates than the comparison cohort women in all strata of comorbidity, particularly in the first year of follow-up. Such an effect is probably due to a prothrombotic state associated with the cancer and cancer-directed treatments such as surgery, chemotherapy, and antihormonal therapies.[14,26,27] Other medications used to treat cancer symptoms and comorbid conditions, such as NSAIDs and glucocorticoids, could elevate VTE risk.[28,29] With increasing CCI score, the rates of VTE in the two cohorts approached each other. This finding may be explained by a potential greater effect of the cumulative comorbidity burden on the VTE risk, while the effect of breast cancer remains similar within each strata of comorbidity.

1
2
3
4 Therefore the presence of comorbidity may be a factor worth considering in future prediction models.
5
6

7
8 This study was based on a nationwide cohort of breast cancer patients, and we achieved complete
9
10 follow-up through the CRS, limiting selection bias.
11

12
13 Despite these strengths, there are several study limitations to consider. The positive predictive values
14
15 for the CCI diseases recorded in the DNRP are high compared to medical record review.[31] However,
16
17 outpatient data were not registered before 1995, and the impact of any resulting misclassification of
18
19 comorbidities on estimates of the interaction contrast are unclear.[32] The definition of VTE included
20
21 both in- and outpatient discharge VTE diagnoses. However, the accuracy of these diagnoses vary for
22
23 type of diagnosis and hospital department, with the highest PPV of 75% for inpatient diagnoses.[24]
24
25

26
27 Any bias resulting from the potential rate of misclassification could be affected by a diagnosis of
28
29 breast cancer and lead to surveillance bias, because patients receive thorough medical care,
30
31 particularly in the initial years following diagnosis.[33] In addition, intravenous catheters used in
32
33 connection with cancer surgery or chemotherapy are linked to VTE.[34] Such associations could affect
34
35 the accuracy of DVT diagnoses. Furthermore, we lacked information on use of hormone replacement
36
37 therapy, other medications, and intravenous catheters, which could independently affect VTE risk.
38
39

40
41 In summary, we found only little interaction between breast cancer and the CCI score on the rate of VTE. While
42
43 there was little interaction, it does appear that patients and physicians should consider comorbidities when
44
45 contemplating prophylactic anticoagulation for breast cancer patients.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Characteristics of the breast cancer and comparison cohorts.				
	Breast cancer cohort		Matched comparison cohort	
	Women, N	(%)	Women, N	(%)
Number of patients				
0–1 year of follow-up	62,376		304,803	
>1–5 years of follow-up	57,857		296,326	
Age group in years				
0–59	27,013	(43)	134,598	(44)
60–69	17,065	(27)	81,640	(27)
70–79	10,846	(17)	53,000	(17)
≥80	7,452	(12)	35,565	(12)
Year of cancer diagnosis/index date^a				
1995–1999	16,949	(27)	83,263	(27)
2000–2004	18,894	(30)	92,488	(30)
2005–2010	26,533	(43)	129,052	(42)
Cancer stage				
Local	28,936	(46)	N/A	
Regional	24,210	(39)	N/A	
Distant	3,302	(5.3)	N/A	
Unknown	5,928	(9.5)	N/A	
Charlson Comorbidity Index score				
0	46,856	(75)	231,713	(76)
1	8,037	(13)	38,854	(13)
2–3	6,437	(10)	30,419	(10)
≥4	1,047	(1.7)	3,817	(1.3)
Individual comorbidities in the Charlson Comorbidity Index				
Myocardial infarction	1,086	(1.7)	4,909	(1.6)
Congestive heart failure	1,258	(2.0)	5,333	(1.7)
Peripheral vascular disease	1,267	(2.0)	5,598	(1.8)
Cerebrovascular disease	2,919	(4.7)	13,530	(4.4)
Dementia	426	(0.7)	1,888	(0.6)
Chronic pulmonary disease	3,118	(5.0)	14,446	(4.7)
Connective tissue disease	1,471	(2.4)	6,766	(2.2)
Ulcer disease	1,623	(2.6)	7,509	(2.5)
Mild liver disease	402	(0.6)	1,764	(0.6)
Diabetes I and II	1,751	(2.8)	7,837	(2.6)
Hemiplegia	87	(0.1)	365	(0.1)
Moderate to severe renal disease	445	(0.7)	1,892	(0.6)
Diabetes with end-organ damage	653	(1.0)	2,832	(0.9)
Any tumor^b	3,221	(5.2)	15,196	(5.0)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Leukemia	66	(0.1)	273	(0.1)
Lymphoma	189	(0.3)	859	(0.3)
Moderate to severe liver disease	77	(0.1)	311	(0.1)
Metastatic solid tumor	296	(0.5)	1,320	(0.4)
AIDS	6	(0)	30	(0)
Other comorbidities				
Atrial fibrillation	567	(0.9)	2,453	(0.8)
Obesity	1,330	(2.1)	5,984	(2.0)
Cases of VTE^c				
0–1 year of follow-up				
DVT	195	(39)	309	(46)
PE	178	(35)	235	(35)
Other VTEs	129	(26)	124	(19)
>1–5 years of follow-up				
DVT	333	(26)	1,025	(34)
PE	289	(22)	827	(28)
Other VTEs	167	(13)	456	(15)

^aDefined as date of breast cancer diagnosis for the breast cancer cohort and date of sampling for the matched cohort.

^bExcluding breast cancer.

^cPercentages are calculated based on the number of women with VTE.

Table 2. 0–1 year and >1–5 year VTE rate, interaction contrasts (IC), and VTE rate ratio by Charlson Comorbidity Index (CCI) score for the breast cancer and matched comparison cohorts.

0–1 year follow-up						
CCI score	Cohort	Number of VTEs	Person-years	Rate (95% CI)	IC (95% CI)	HR (95% CI)
0	Breast	324	45,342	7.1 (6.4, 7.9)	Ref	4.8 (4.1, 5.6)
0	Comparison	346	229,978	1.5 (1.4, 1.7)		
1	Breast	93	7,543	12 (10, 15)	3.2 (0.5, 5.9)	3.5 (2.7, 4.6)
1	Comparison	134	37,966	3.5 (3.0, 4.2)		
2–3	Breast	70	5,936	12 (9.2, 15)	1.2 (-1.8, 4.2)	2.4 (1.8, 3.1)
2–3	Comparison	146	29,201	5.0 (4.2, 5.8)		
≥4	Breast	15	910	17 (9.2, 26)	-1.3 (-11, 7.9)	1.3 (0.7, 2.4)
≥4	Comparison	42	3,455	12 (8.8, 16)		
>1–5 year follow-up						
CCI score	Cohort	Number of VTEs	Person-years	Std. Rate (95%CI)	IC (95%CI)	HR (95% CI)
0	Breast	533	135,618	4.3 (3.9, 4.6)	Ref	2.2 (2.0, 2.4)
0	Comparison	1384	747,209	2.1 (2.0, 2.2)		
1	Breast	136	19,861	6.4 (5.3, 7.6)	0.9 (-0.4, 2.1)	1.7 (1.4, 2.1)
1	Comparison	436	109,138	3.4 (3.0, 3.7)		
2–3	Breast	100	14,766	6.1 (4.7, 7.5)	-0.5 (-2.1, 1.0)	1.2 (1.0, 1.6)
2–3	Comparison	433	79,310	4.5 (4.0, 5.0)		
≥4	Breast	20	1,834	10 (3.9, 17)	2.3 (-4.3, 8.9)	1.5 (0.9, 2.5)
≥4	Comparison	55	7,825	5.8 (4.0, 7.5)		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix. ICD-codes identifying breast cancer, VTE, and comorbidities.		
ICD codes	ICD-8	ICD-10
Breast cancer	174	C50
Pulmonary embolism	45099	I26
Deep venous thrombosis	45100	I801, I802, I803
Other VTEs	45101, 45108, 45109, 45190, 45191, 45192, 45199, 45299, 453	I800, I808, I809, I81, I82
Myocardial infarction	410	I21, I22, I23
Congestive heart failure	427.09, 427.10, 427.11, 427.19, 428.99, 782.49	I50, I11.0, I13.0, I13.2
Peripheral vascular disease	440, 441, 442, 443, 444, 445	I70, I71, I72, I73, I74, I77
Cerebrovascular disease	430-438	I60-I69, G45, G46
Dementia	290.09-290.19, 293.09	F00-F03, F05.1, G30
Chronic pulmonary disease	490-493, 515-518	J40-J47, J60-J67, J68.4, J70.1, J70.3, J84.1, J92.0, J96.1, J98.2, J98.3
Connective tissue disease	712, 716, 734, 446, 135.99	M05, M06, M08, M09, M30, M31, M32, M33, M34, M35, M36, D86
Ulcer disease	530.91, 530.98, 531- 534	K22.1, K25-K28
Mild liver disease	571, 573.01, 573.04	B18, K70.0-K70.3, K70.9, K71, K73, K74, K76.0
Diabetes type1	249.00, 249.06, 249.07, 249.09	E10.0, E10.1, E10.9
Diabetes type2	250.00, 250.06, 250.07, 250.09	E11.0, E11.1, E11.9
Hemiplegia	344	G81, G82
Moderate to severe renal disease	403, 404, 580- 583, 584, 590.09, 593.19, 753.10- 753.19, 792	I12, I13, N00-N05, N07, N11, N14, N17-N19, Q61

Diabetes with end organ damage		
Type1	249.01-249.05, 249.08	E10.2-E10.8
Type2	250.01-250.05, 250.08	E11.2-E11.8
Any tumor, except breast cancer	140-194, except 174	C00-C75, except C50
Leukemia	204-207	C91-C95
Lymphoma	200-203,275.59	C81-C85, C88, C90, C96
Moderate to severe liver disease	070.00, 070.02, 070.04, 070.06, 070.08, 573.00, 456.00-456.09	B15.0, B16.0, B16.2, B19.0, K70.4, K72, K76.6, I85
Metastatic solid tumor	195-198, 199	C76-C80
AIDS	079.83	B21-B24
Atrial fibrillation	42793	I489B
Obesity	27799	E66

Author contributions

AGO, HTS, and TLL conceived and designed the study. AGO, EHP, HTS, TLL acquired, analyzed, and interpreted the data. AGO wrote the first draft and EHP, JPG, PWN, HTS, MV and TLL reviewed, revised, and approved the manuscript.

Funding sources

The study was supported by the Danish Cancer Society (grant no. R73-A4284-13-S17); the Danish Agency for Science, Technology and Innovation (Record number: 10-084581).; Karen Elise Jensen Foundation; Aarhus University Research Foundation; the Clinical Epidemiology Research Foundation, Aarhus University; Aalborg Hospital, Region North Denmark. The funding sources had no role in design, analysis and interpretation of the study.

Conflict of Interest

The Department of Clinical Epidemiology, Aarhus University Hospital, receives funding for other studies from companies in the form of research grants to (and administered by) Aarhus University. None of these studies have any relation to the present study. The authors declare no conflict of interest.

References

- (1) Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. *Cancer* 2011;117:1334-1349.
- (2) Sorensen HT, Mellekjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. *N Engl J Med* 2000;343:1846-1850.
- (3) Cronin-Fenton DP, Sondergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. *Br J Cancer* 2010;103:947-953.
- (4) Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. *Arch Intern Med* 2000;160:809-815.
- (5) Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. *JAMA* 2005;293:715-722.

1
2
3
4 (6) Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the
5
6
7 impact on survival in breast cancer patients. *J Clin Oncol* 2007;25:70-76.
8
9

10
11 (7) Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends
12
13 for venous thromboembolism among hospitalized cancer patients. *Cancer* 2007;110:2339-2346.
14
15

16
17 (8) Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous
18
19 catheters in cancer patients. *J Clin Oncol* 2003;21:3665-3675.
20
21

22
23 (9) Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of
24
25 cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010;127:2893-2917.
26
27

28
29 (10) Cronin-Fenton DP, Norgaard M, Jacobsen J, Garne JP, Ewertz M, Lash TL, et al. Comorbidity and
30
31 survival of Danish breast cancer patients from 1995 to 2005. *Br J Cancer* 2007;96:1462-1468.
32
33

34
35 (11) Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary heart disease,
36
37 stroke, and venous thromboembolism. *Am J Epidemiol* 2005;162:975-982.
38
39

40
41 (12) Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW, et al. An association
42
43 between atherosclerosis and venous thrombosis. *N Engl J Med* 2003;348:1435-1441.
44
45

46
47 (13) Breart G, Cooper C, Meyer O, Speirs C, Deltour N, Reginster JY. Osteoporosis and venous
48
49 thromboembolism: a retrospective cohort study in the UK General Practice Research Database.
50
51

52
53 Osteoporos Int 2010;21:1181-1187.
54
55
56
57
58
59
60

- 1
2
3
4 (14) Anderson FA,Jr, Spencer FA. Risk factors for venous thromboembolism. *Circulation* 2003;107:19-
5
6
7 16.
8
9
10
11 (15) Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic
12
13 comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373-383.
14
15
16
17 (16) Rothman KJ, Greenland S, Lash TL. Concepts of Interaction. *Modern Epidemiology*. 3rd ed.
18
19 Philadelphia: Lippincott Williams & Wilkins; 2008:71-86.
20
21
22
23 (17) Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk
24
25 factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism
26
27 etiology. *Arch Intern Med* 2002;162:1182-1189.
28
29
30
31
32 (18) Lip GY, Tse HF. Management of atrial fibrillation. *Lancet* 2007;370:604-618.
33
34
35
36 (19) Frank L. Epidemiology. When an entire country is a cohort. *Science* 2000;287:2398-2399.
37
38
39
40 (20) Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A
41
42 cohort of eight million persons. *Dan Med Bull* 2006;53:441-449.
43
44
45
46 (21) Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry--history, content,
47
48 quality and use. *Dan Med Bull* 1997;44:535-539.
49
50
51
52 (22) Gjerstorff ML. The Danish Cancer Registry. *Scand J Public Health* 2011;39(7 Suppl):42-45.
53
54
55
56
57
58
59
60

1
2
3
4 (23) Andersen TF, Madsen M, Jorgensen J, Mellekjoer L, Olsen JH. The Danish National Hospital
5 Register. A valuable source of data for modern health sciences. *Dan Med Bull* 1999;46:263-268.
6
7

8
9
10 (24) Severinsen MT, Kristensen SR, Overvad K, Dethlefsen C, Tjonneland A, Johnsen SP. Venous
11 thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with
12 caution. *J Clin Epidemiol* 2010;63:223-228.
13
14
15

16 (25) Andersen PK, Geskus RB, de Witte T, Putter H. Competing risks in epidemiology: possibilities and
17 pitfalls. *Int J Epidemiol* 2012;41:861-870.
18
19
20

21 (26) Mandala M, Barni S, Prins M, Labianca R, Tondini C, Russo L, et al. Acquired and inherited risk
22 factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy:
23 a prospective trial. *Ann Oncol* 2010;21:871-876.
24
25
26

27 (27) Degen JL, Palumbo JS. Hemostatic factors, innate immunity and malignancy. *Thromb Res*
28 2012;129 Suppl 1:S1-5.
29
30
31

32 (28) Johannesdottir SA, Horvath-Puho E, Dekkers OM, Cannegieter SC, Jorgensen JO, Ehrenstein V, et
33 al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-
34 control study. *JAMA Intern Med* 2013;173:743-752.
35
36
37

38 (29) Schmidt M, Christiansen CF, Horvath-Puho E, Glynn RJ, Rothman KJ, Sorensen HT. Non-steroidal
39 anti-inflammatory drug use and risk of venous thromboembolism. *J Thromb Haemost* 2011;9:1326-
40 1333.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 (30) Jensen AR, Overgaard J, Storm HH. Validity of breast cancer in the Danish Cancer Registry. A
5
6 study based on clinical records from one county in Denmark. Eur J Cancer Prev 2002;11:359-364.
7
8

9
10 (31) Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10
11
12 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based
13
14 Danish National Registry of Patients. BMC Med Res Methodol 2011;11:83.
15
16

17
18 (32) Greenland S. The effect of misclassification in the presence of covariates. Am J Epidemiol
19
20
21 1980;112:564-569.
22
23

24
25 (33) Moller S, Jensen MB, Ejlersen B, Bjerre KD, Larsen M, Hansen HB, et al. The clinical database and
26
27 the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years
28
29 experience and future promise. Acta Oncol 2008;47:506-524.
30
31

32
33 (34) Caine GJ, Stonelake PS, Rea D, Lip GY. Coagulopathic complications in breast cancer. Cancer
34
35
36 2003;98:1578-1586.
37
38

BMJ Open

Impact of comorbidity on risk of venous thromboembolism in breast cancer patients – A Danish population-based cohort study.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005082.R1
Article Type:	Research
Date Submitted by the Author:	11-May-2014
Complete List of Authors:	Ording, Anne; Aarhus University Hospital, Department of clinical Epidemiology Horváth-Puhó, Erzsébet; Aarhus university Hospital, Department of Clinical Epidemiology Garne, Jens Peter; Aalborg University Hospital, Breast Clinic Nyström, Petra; Uppsala University Hospital, Department of Oncology Vyberg, Mogens; Aalborg University Hospital, Institute of Pathology Toft Sørensen, Henrik; Aarhus university Hospital, Department of Clinical Epidemiology; Aarhus University Hospital, Department of Clinical Epidemiology Lash, Timothy; Emory University, Department of Epidemiology; Aarhus university Hospital, Department of Clinical Epidemiology
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Haematology (incl blood transfusion), Epidemiology
Keywords:	EPIDEMIOLOGY, ONCOLOGY, Bleeding disorders & coagulopathies < HAEMATOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4 1 **Title: Impact of comorbidity on risk of venous thromboembolism in breast cancer patients – A Danish**
5
6 2 **population-based cohort study**
7
8
9

10 3 **Authors and affiliations**

11 4 Anne Gulbech Ording¹

12 5 Erzsébet Horváth-Puhó¹

13 6 Jens Peter Garne²

14 7 Petra Witt Nyström³

15 8 Mogens Vyberg⁴

16 9 Henrik Toft Sørensen¹

17 10 Timothy L. Lash^{1,5}

18 11 ¹Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

19 12 ²Breast Clinic, Aalborg University Hospital, Aalborg, Denmark

20 13 ³Department of Oncology, Uppsala University Hospital, Uppsala, Sweden

21 14 ⁴Institute of Pathology, Aalborg University Hospital, Aalborg, Denmark

22 15 ⁵Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA

23 16 **Corresponding author**

24 17 Anne G. Ording, Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200

25 18 Aarhus N. E-mail address: ao@dce.au.dk; Telephone: +45 87 16 80 63; Fax: +45 87 16 72 15

26 19
27
28 20 **Running title:** Breast cancer, comorbidity and risk of VTE

29 21 **Key words:** Breast neoplasms, comorbidity, morbidity, venous thrombosis, haemostasis, epidemiology

30 22 **Abstract word count: 219, manuscript word count: 2,472.**
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 23 **Abstract**

5
6
7 24 Objectives: To assess the interaction between comorbidity and breast cancer (BC) on the rate of venous
8
9 25 thromboembolism (VTE) beyond what can be explained by the independent effects of BC and comorbidity.

10
11 26 Design: Population-based matched cohort study.

12
13
14 27 Setting: Denmark.

15
16 28 Participants: Danish BC patients (n=62,376) diagnosed 1995–2010 and a comparison cohort of women without
17
18 29 BC (n=304,803) from the general population matched to the BC patients on year of birth in five-year intervals
19
20 30 and on the specific diseases included in the Charlson Comorbidity Index (CCI) and atrial fibrillation and obesity.

21
22
23 31 Measures: The rate ratios of VTE per 1000 person-years (PYs) were computed by comorbidity levels using the
24
25 32 CCI, and interaction contrasts (IC) were calculated as a measure of the excess or deficit VTE rate not explained
26
27 33 by the independent effects of BC and comorbidity.

28
29
30 34 Results: Among BC patients with a CCI score of 1, the 0-1 year VTE rate was 12 per 1000 person-years (PYs),
31
32 35 and interaction accounted for 10% of the rate (IC= 3.2, 95% confidence interval (CI), 0.5, 5.9). Among BC
33
34 36 patients with CCI ≥ 4 , the VTE rate was 17, and interaction accounted for 8% of the rate (IC= 1.2, 95%CI, -1.8,
35
36 37 4.2). There was no interaction during 2-5 years of follow-up.

37
38
39 38 Conclusion: There was only little interaction between BC and the CCI score on the rate of VTE.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article summary

- The study included all Danish breast cancer patients diagnosed 1995–2010 and a comparison cohort of women from the general population free of breast cancer. The study had complete follow-up on all participants from the nationwide Danish Civil Registration System.
- The study was conducted in a government financed health care system with equal access for the entire Danish population.
- The validity of the Danish National Registry of Patients as a source of information on comorbidity and VTE has varying completeness and validity for different diseases.
- The CCI as a measure of the combined burden of comorbidity does not allow for estimation of disease severity and duration.

60 Background

61 Venous thromboembolism (VTE), i.e., deep venous thrombosis (DVT) and pulmonary embolism (PE), is
62 associated with high morbidity and mortality, in particular during hospitalization.¹ Cancer and VTE are
63 strongly related and VTE can be a marker of occult cancer as well as a serious complication of cancer.²
64 Cancer-associated VTE risk is up to seven times higher compared to that of the general population,³⁻⁵
65 and the rate is mainly increased during the first year following cancer diagnosis.^{3,6} Important risk
66 factors include cancer type and cancer stage, but may also be related to treatment including
67 chemotherapy and central venous catheters used for treatment administration.^{1,7,8}
68 Breast cancer is the most common cancer among women in most of the developed world,⁹ and an
69 estimated 20% of patients are burdened with major comorbid conditions at diagnosis.¹⁰ While there is
70 evidence for a link between some diseases, such as stroke, heart failure, and osteoporosis, and risk of
71 VTE,¹¹⁻¹⁴ it is largely unknown how chronic diseases in breast cancer affect the risk of VTE compared to
72 the general population free of breast cancer.

73 To our knowledge, no studies have compared the risk of VTE among BC patients to a comparison
74 cohort of women free of BC from the general population and accounted for comorbidity. We
75 computed the interaction contrast (IC) as a measure of interaction between breast cancer and
76 comorbidity levels using the Charlson Comorbidity Index (CCI) as a measure of comorbidity.¹⁵ The IC is
77 an estimate of the VTE rate that cannot be explained by the effects of breast cancer or comorbidity
78 acting alone.¹⁶

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

80 **Methods**

81 *Design and setting*

82 To compare VTE rates in a cohort of breast cancer patients with corresponding rates in a cohort of
83 women free of breast cancer, we designed a nationwide cohort study including all patients
84 diagnosed with breast cancer in Denmark between 1995 and 2010 and a comparison cohort of
85 women selected from the general population. Women in the comparison cohort were matched to
86 each breast cancer patient on year of birth in five-year intervals and on the specific diseases
87 included in the CCI, and on history of atrial fibrillation and obesity, as atrial fibrillation is treated
88 with anticoagulation and obesity is a risk factor for VTE.^{15,17,18}

89 The study used administrative and medical registries in Denmark, where the national health care
90 system provides tax-supported access to primary care and hospitals for all legal residents.¹⁹ The
91 Civil Registration System (CRS) maintains up-to-date information on vital and civil status for all
92 Danish residents.²⁰ Since 1968, all residents of Denmark have been assigned a Civil Personal
93 Registration (CPR) number, which facilitates accurate linkage between medical registries. This
94 study made use of such registries to provide information on breast cancer and other hospital
95 diagnoses (see appendix).

96 *Ascertainment of the breast cancer and comparison cohorts*

97 The Danish Cancer Registry (DCR) was established in 1943 and records all cancers diagnosed in
98 Denmark.^{21,22} We identified all female breast cancer patients diagnosed between 1995 and 2010 and
99 excluded patients with a VTE diagnosis preceding the index (diagnosis) date. For women in the

1
2
3
4 100 comparison cohort, the index date was defined as the date of breast cancer diagnosis for the matched
5
6
7 101 case.

8
9
10 102 From the CRS, we selected up to five women from the general population and matched them without
11
12 103 replacement to each breast cancer patient on age (5-year intervals) and on hospital history of specific
13
14 104 comorbidities included in the CCI,¹⁵ and on presence/absence of atrial fibrillation and obesity. We
15
16
17 105 were unable to find matched comparison women to 428 breast cancer patients due to high age and
18
19
20 106 many comorbidities, which precluded matching. Women in the comparison cohort could not have
21
22 107 previous diagnostic codes for breast cancer or VTE as of the date of breast cancer diagnosis for the
23
24
25 108 corresponding case but were eligible for inclusion in the breast cancer cohort if they developed breast
26
27 109 cancer.

30 110

31 111 *Comorbidity*

32
33
34
35 112 The Danish National Registry of Patients (DNRP) contains information on all non-psychiatric discharge
36
37 113 diagnoses for inpatient hospitalizations since 1977. Information on visits to outpatient specialist and
38
39
40 114 emergency departments was added from 1995. The DNRP records diagnoses and dates of hospital
41
42 115 contacts.²³ This registry was used to identify all diagnoses of diseases included in the CCI,¹⁵ as well as
43
44
45 116 atrial fibrillation and obesity, for members of the two cohorts (see Appendix). Atrial fibrillation and
46
47 117 obesity were included in the CCI with a weight of one.

48 49 50 118

51 119 *Venous thromboembolism*

52
53
54
55 120 The study outcome was VTE, defined as any in- or outpatient discharge diagnosis of PE, DVT, or other
56
57
58
59
60

1
2
3
4 121 VTE diagnosed after the index date (see Appendix), thereby excluding VTE that was only diagnosed at
5
6
7 122 emergency departments due to a low positive predictive value%.²⁴ Because of the little impact on
8
9
10 123 mortality risk associated with DVT alone, patients coded as having both DVT and PE on their first
11
12 124 diagnosis date were classified as PE patients.
13

14 15 125 16 17 126 *Follow-up*

18
19
20 127 The breast cancer and comparison cohorts were followed from the index date until the first
21
22 128 occurrence of VTE, death, emigration or five years of follow-up, whichever came first. If a matched
23
24
25 129 comparison cohort member received a breast cancer diagnosis, follow-up was censored and the
26
27 130 woman was switched to the breast cancer cohort. The person-time was divided into two survivor
28
29
30 131 cohorts, the first with one year of follow-up and the second with two to five years of follow-up.
31

32 132 33 34 35 133 *Statistical analysis*

36
37 134 First, we computed proportions of women in the breast cancer cohort and the matched comparison
38
39
40 135 cohort within categories of age (0–59, 60–69, 70–79, and ≥80 years), index year (1995–1999, 2000–
41
42 136 2004, and 2005–2010), baseline CCI score (0, 1, 2–3, ≥4), individual CCI comorbidities,
43
44
45 137 presence/absence of atrial fibrillation and obesity, and—for the breast cancer cohort—breast cancer
46
47 138 stage at diagnosis (local, regional, distant, or unknown).
48
49

50 139 Next, we computed cumulative incidence estimates for VTE, which takes into account the competing
51
52 140 risk of death (an event that precludes subsequent VTE occurrence).²⁵
53
54

55 141 We then computed the rate of VTE within the categories described above for the two cohorts and
56
57
58
59
60

1
2
3
4
5 142 created Cox proportional hazard regression models to compute the hazard ratios (HRs) as a measure
6
7 143 of the VTE rate ratio adjusted for age (continuous) and year of breast cancer diagnosis (1995–1999 vs.
8
9 144 2005–2010, 2000–2004 vs. 2005–2010) to compute rate ratios for VTE within strata of comorbidity.
10
11
12 145 As comorbid conditions were matched factors, the matching had to be dissolved in all adjusted
13
14 146 analyses and for analyses of the 2–5 year survival cohort. To account for changes in the age
15
16
17 147 distribution at one year of follow-up, VTE rates for the 2–5 year survivor cohort were standardized to
18
19
20 148 the age distribution of the breast cancer patients as of their index dates. The proportionality
21
22 149 assumption in Cox models were examined with log minus log plots, and both this and the linearity
23
24
25 150 assumption of the effect of age were found to be acceptable. The interaction between breast cancer
26
27 151 and comorbidity on the rate of VTE was examined by calculating the IC, which measures the excess or
28
29
30 152 deficit rate of VTE above or below that expected given the baseline VTE rate, the effect of breast
31
32 153 cancer on the VTE rate, and the effect of comorbidity on the VTE rate, based on additivity of effects. It
33
34
35 154 is calculated as the difference between the rate differences (VTE rate in the breast cancer cohort
36
37 155 minus the VTE rate in the comparison cohort) in the strata with and without comorbidity.¹⁶ The IC is a
38
39
40 156 measure of the synergistic or antagonistic interaction between two factors that cannot be explained
41
42 157 by their individual effects.
43
44
45 158 Analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, NC).
46
47 159 The study was approved by the Danish Data Protection Agency (2011-41-6174).
48
49
50 160

51 52 161 **Results**

53
54
55 162 Descriptive statistics of the cohorts are shown in Table 1. The study included 62,376 breast cancer
56
57
58
59
60

1
2
3
4 163 patients and 304,803 women from the general population matched to the breast cancer patients
5
6
7 164 diagnosed between 1995 and 2010. The median age in the breast cancer cohort was 62.3 years
8
9
10 165 (inter-quartile range (IQR), 52.8, 72.3), and 62.0 (IQR: 52.6, 72.9) in the comparison cohort. In the
11
12 166 breast cancer and comparison cohort, 75% and 76% of all women had a CCI score of 0 at the index
13
14
15 167 date. During the first year of follow-up, there were 502 (0.8%) and 668 (0.2%) cases of VTE in the
16
17 168 breast cancer and the matched comparison cohort, respectively, of which 39% vs. 46% were DVT, 35%
18
19
20 169 were PE in both cohorts, and 26% vs. 19% were other VTEs, respectively. By five years of follow-up, an
21
22 170 additional 789 (1.4%) cases of VTE were diagnosed in the breast cancer cohort and 2,308 (0.8%) in the
23
24
25 171 comparison cohort.

26
27
28 172 Table 2 presents the VTE rates, ICs, and adjusted VTE rate ratios for 0–1 year and 2–5 years of follow-
29
30
31 173 up in the breast cancer and comparison cohorts. After taking into account death as a competing risk,
32
33 174 the breast cancer cohort was at higher risk for all types of VTE within 1 year of follow-up (0.80%,
34
35
36 175 95%CI: 0.74, 0.88) and 0.22% (95%CI: 0.20, 0.24), respectively) and at 5 years of follow-up (1.6%,
37
38 176 95%CI: 1.50, 1.73) and 0.93% (95%CI: 0.90, 0.97, respectively). At one year of follow-up, the VTE rate
39
40
41 177 was 8.4 (95% confidence interval (CI), 7.7, 9.2) per 1000 person-years (PY) in the breast cancer cohort
42
43 178 and 2.2 (95% CI, 2.1, 2.4) per 1000 PY in the comparison cohort (data not shown). In all strata of CCI
44
45
46 179 scores, the breast cancer cohort had higher rates of VTE compared to the comparison cohort, but the
47
48 180 corresponding hazard ratios (HRs) decreased with increasing CCI score. The HR for VTE was 4.8
49
50
51 181 (95%CI, 4.1, 5.6) for a CCI score of 0, and 1.3 (95%CI, 0.7, 2.4) for a CCI score of ≥ 4 . During 2–5 years
52
53 182 of follow-up, the corresponding HRs were 2.2 (95%CI, 2.0, 2.4) for a CCI score of 0 and 1.5 (95%CI, 0.9,
54
55
56 183 2.5) for a CCI score of ≥ 4 .

1
2
3
4 184 The IC analysis revealed a small amount of interaction between breast cancer and the CCI score,
5
6
7 185 which weakened with increasing CCI score, suggesting that the combined effect of breast cancer and
8
9
10 186 comorbidity mainly impacts the VTE rates in presence of low comorbidity levels. Interaction
11
12 187 accounted for 3.2 (95%CI, 0.5, 5.9) cases of VTE per 1000 PY for a CCI score of 1, 1.2 (95%CI, -1.8, 4.2)
13
14 188 cases of VTE for a CCI score of 2–3, and -1.3 (95%CI, -11, 7.9) cases of VTE for a CCI score of ≥ 4 per
15
16
17 189 1000 PY, representing 27%, 10%, and -7.6% of total VTE rates, respectively. During 2–5 years of
18
19
20 190 follow-up weak interaction was only observed for a CCI score of ≥ 4 (IC, 2.3, 95%CI, -4.3, 8.9/1000PY),
21
22 191 corresponding to 23% of the total VTE rate.
23
24

25 192 Discussion

26
27
28
29 193 In this nationwide study, the breast cancer cohort had elevated rates of VTE compared to women
30
31 194 from the comparison cohort in all categories of comorbidity. However, comparing the breast cancer
32
33
34 195 cohort to the comparison cohort within levels of the CCI score, VTE rate differences remained nearly
35
36 196 constant as the comorbidity level increased, whereas the rate ratios declined with increasing CCI
37
38
39 197 score. We found that there was only a small amount of interaction between breast cancer and the CCI
40
41 198 score on the VTE rate, which primarily was observed during the first year after breast cancer diagnosis
42
43
44 199 for patients with a CCI score of 1. This pattern of effects and interactions suggests that comorbidity
45
46 200 and breast cancer or its treatment effect the rate of VTE for breast cancer patients with a CCI score of
47
48
49 201 1 and in the first year of follow-up. Previous studies have found that BC does not confer a large
50
51 202 increased risk of VTE compared to many other cancer types,³ which may provide one explanation for
52
53
54 203 the relatively small amount of interaction in BC patients compared to women from the general
55
56 204 population.
57
58
59
60

1
2
3
4 205 Interaction contrasts were negative in some analyses, although often imprecisely measured. Negative
5
6
7 206 interaction contrasts suggest that the joint effect of breast cancer and comorbidity is less than
8
9
10 207 expected from their individual effects. In women with multiple comorbidities, and at longer times of
11
12 208 follow-up, the independent effects of comorbidity and breast cancer, therefore, dominate the overall
13
14
15 209 risk of VTE, possibly due to the higher baseline risk of VTE contributed by each of these factors.
16

17 210
18
19
20 211 In our study, breast cancer patients had higher VTE rates than the comparison cohort women in all
21
22 212 strata of comorbidity, particularly in the first year of follow-up. Such an effect is probably due to a
23
24
25 213 prothrombotic state associated with the cancer and cancer-directed treatments such as surgery,
26
27 214 chemotherapy, and antihormonal therapies.^{14,26,27} Other medications used to treat cancer symptoms
28
29
30 215 and comorbid conditions, such as NSAIDs and glucocorticoids, could elevate VTE risk.^{28,29} With
31
32 216 increasing CCI score, the rates of VTE in the two cohorts approached each other. This finding may be
33
34
35 217 explained by a potential greater effect of the cumulative comorbidity burden on the VTE risk, while
36
37 218 the effect of breast cancer remains similar within each strata of comorbidity.

38
39
40 219 Therefore the presence of comorbidity may be a factor worth considering in future prediction models.
41

42
43 220 This study was based on a nationwide cohort of breast cancer patients, and we achieved almost
44
45
46 221 complete follow-up through the CRS, limiting selection bias.
47

48 222 Despite these strengths, there are several study limitations to consider. Data on breast cancer
49
50
51 223 obtained from the DCR are virtually complete.³⁰ The positive predictive values for the CCI diseases
52
53 224 recorded in the DNRP are above 80% compared to medical record review.³¹ However, outpatient data
54
55
56 225 were not registered before 1995, and the impact of any resulting misclassification of comorbidities on
57
58
59
60

1
2
3
4 226 estimates of the interaction contrast are unclear.³² The definition of VTE included both in- and
5
6
7 227 outpatient discharge VTE diagnoses, but the accuracy of these diagnoses vary for type of diagnosis
8
9
10 228 and hospital department, with the highest PPV of 75% for inpatient diagnoses.²⁴ To reduce the
11
12 229 number of invalid VTE diagnoses, we only included inpatient and outpatient VTE diagnoses thereby
13
14
15 230 disregarding VTE only diagnosed at emergency departments, which have poor predictive value.²⁴ Any
16
17 231 bias resulting from the potential rate of misclassification could be affected by a diagnosis of breast
18
19
20 232 cancer and lead to surveillance bias, because patients receive thorough medical care, particularly in
21
22 233 the initial years following diagnosis.³³ With increasing CCI score, the VTE rates among the breast
23
24
25 234 cancer patients approach the rates of comparison women, suggesting that the amount of medical
26
27 235 surveillance is more similar between the cohorts with increasing morbidity. In addition, intravenous
28
29
30 236 catheters used in connection with cancer surgery or chemotherapy are linked to VTE.³⁴ Such
31
32 237 associations could affect the accuracy of DVT diagnoses. Furthermore, we lacked information on
33
34
35 238 several important factors, for example cancer treatment, abnormal laboratory findings, other
36
37 239 medications, and intravenous catheters, which could independently affect VTE risk.

38
39
40
41 240 In summary, we found only little interaction between breast cancer and the CCI score on the rate of
42
43 241 VTE. While there was little interaction, it does appear that patients and physicians should consider
44
45
46 242 comorbidities when contemplating prophylactic anticoagulation for breast cancer patients.
47
48
49 243
50
51
52
53 244
54
55
56
57
58
59
60

1
2
3
4
5 245
6
7 246
8
9 247
10
11 248
12
13
14 249
15
16
17 250
18
19
20 251
21
22 252
23
24 253
25
26
27 254
28
29 255
30
31 256
32
33
34 257
35
36 258
37
38 259
39
40 260
41
42
43
44 261
45
46
47
48 262
49
50
51 263
52
53
54
55
56
57
58
59
60

Author contributions

AGO, HTS, and TLL conceived and designed the study. AGO, EHP, HTS, TLL acquired, analyzed, and interpreted the data. AGO wrote the first draft and EHP, JPG, PWN, HTS, MV and TLL reviewed, revised, and approved the manuscript.

Funding sources

The study was supported by the Danish Cancer Society (grant no. R73-A4284-13-S17); the Danish Agency for Science, Technology and Innovation (Record number: 10-084581).; Karen Elise Jensen Foundation; Aarhus University Research Foundation; the Clinical Epidemiology Research Foundation, Aarhus University; Aalborg Hospital, Region North Denmark. The funding sources had no role in design, analysis and interpretation of the study.

Conflict of Interest

The Department of Clinical Epidemiology, Aarhus University Hospital, receives funding for other studies from companies in the form of research grants to (and administered by) Aarhus University. None of these studies have any relation to the present study. The authors declare no conflict of interest.

Data Sharing Statement

No additional data available

References

- (1) Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. *Cancer* 2011 Apr 1;117(7):1334-1349.
- (2) Sorensen HT, Mellekjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. *N Engl J Med* 2000 Dec 21;343(25):1846-1850.
- (3) Cronin-Fenton DP, Sondergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. *Br J Cancer* 2010 Sep 28;103(7):947-953.
- (4) Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. *Arch Intern Med* 2000 Mar 27;160(6):809-815.
- (5) Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. *JAMA* 2005 Feb 9;293(6):715-722.
- (6) Chew HK, Wun T, Harvey DJ, et al. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. *J Clin Oncol* 2007 Jan 1;25(1):70-76.
- (7) Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. *Cancer* 2007 Nov 15;110(10):2339-2346.
- (8) Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. *J Clin Oncol* 2003 Oct 1;21(19):3665-3675.

- 1
2
3
4 282 (9) Ferlay J, Shin HR, Bray F, Forman D, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN
5
6
7 283 2008. *Int J Cancer* 2010 Dec 15;127(12):2893-2917.
8
9
10 284 (10) Cronin-Fenton DP, Norgaard M, et al. Comorbidity and survival of Danish breast cancer patients from 1995
11
12 285 to 2005. *Br J Cancer* 2007 May 7;96(9):1462-1468.
13
14
15
16 286 (11) Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke,
17
18 287 and venous thromboembolism. *Am J Epidemiol* 2005 Nov 15;162(10):975-982.
19
20
21
22 288 (12) Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. *N*
23
24 289 *Engl J Med* 2003 Apr 10;348(15):1435-1441.
25
26
27
28 290 (13) Breart G, Cooper C, Meyer O, et al. Osteoporosis and venous thromboembolism: a retrospective cohort
29
30 291 study in the UK General Practice Research Database. *Osteoporos Int* 2010 Jul;21(7):1181-1187.
31
32
33 292 (14) Anderson FA, Jr, Spencer FA. Risk factors for venous thromboembolism. *Circulation* 2003 Jun 17;107(23
34
35 293 Suppl 1):I9-16.
36
37
38
39 294 (15) Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal
40
41 295 studies: development and validation. *J Chronic Dis* 1987;40(5):373-383.
42
43
44
45 296 (16) Rothman KJ, Greenland S, Lash TL. *Concepts of Interaction. Modern Epidemiology*. 3rd ed. Philadelphia:
46
47 297 Lippincott Williams & Wilkins; 2008. p. 71-86.
48
49
50
51 298 (17) Tsai AW, Cushman M, Rosamond WD, et al. Cardiovascular risk factors and venous thromboembolism
52
53 299 incidence: the longitudinal investigation of thromboembolism etiology. *Arch Intern Med* 2002 May
54
55 300 27;162(10):1182-1189.
56
57
58
59
60

- 1
2
3
4 301 (18) Lip GY, Tse HF. Management of atrial fibrillation. *Lancet* 2007 Aug 18;370(9587):604-618.
5
6
7
8 302 (19) Frank L. *Epidemiology*. When an entire country is a cohort. *Science* 2000 Mar 31;287(5462):2398-2399.
9
10
11 303 (20) Pedersen CB, Gotzsche H, Moller JO, et al. The Danish Civil Registration System. A cohort of eight million
12
13
14 304 persons. *Dan Med Bull* 2006 Nov;53(4):441-449.
15
16
17 305 (21) Storm HH, Michelsen EV, Clemmensen IH, et al. The Danish Cancer Registry--history, content, quality and
18
19
20 306 use. *Dan Med Bull* 1997 Nov;44(5):535-539.
21
22
23 307 (22) Gjerstorff ML. The Danish Cancer Registry. *Scand J Public Health* 2011 Jul;39(7 Suppl):42-45.
24
25
26 308 (23) Andersen TF, Madsen M, Jorgensen J, et al. The Danish National Hospital Register. A valuable source of
27
28
29 309 data for modern health sciences. *Dan Med Bull* 1999 Jun;46(3):263-268.
30
31
32 310 (24) Severinsen MT, Kristensen SR, Overvad K, et al. Venous thromboembolism discharge diagnoses in the
33
34
35 311 Danish National Patient Registry should be used with caution. *J Clin Epidemiol* 2010 Feb;63(2):223-228.
36
37
38 312 (25) Andersen PK, Geskus RB, de Witte T, et al. Competing risks in epidemiology: possibilities and pitfalls. *Int J*
39
40
41 313 *Epidemiol* 2012 Jun;41(3):861-870.
42
43
44 314 (26) Mandala M, Barni S, Prins M, et al. Acquired and inherited risk factors for developing venous
45
46 315 thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. *Ann Oncol* 2010
47
48
49 316 Apr;21(4):871-876.
50
51
52 317 (27) Degen JL, Palumbo JS. Hemostatic factors, innate immunity and malignancy. *Thromb Res* 2012 Apr;129
53
54 318 Suppl 1:S1-5.
55
56
57
58
59
60

- 1
2
3
4 319 (28) Johannesdottir SA, Horvath-Puho E, Dekkers OM, et al. Use of glucocorticoids and risk of venous
5
6
7 320 thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 2013 May
8
9 321 13;173(9):743-752.
10
11
12
13 322 (29) Schmidt M, Christiansen CF, Horvath-Puho E, et al. Non-steroidal anti-inflammatory drug use and risk of
14
15 323 venous thromboembolism. J Thromb Haemost 2011 Jul;9(7):1326-1333.
16
17
18
19 324 (30) Jensen AR, Overgaard J, Storm HH. Validity of breast cancer in the Danish Cancer Registry. A study based
20
21 325 on clinical records from one county in Denmark. Eur J Cancer Prev 2002 Aug;11(4):359-364.
22
23
24 326 (31) Thygesen SK, Christiansen CF, Christensen S, et al. The predictive value of ICD-10 diagnostic coding used to
25
26 327 assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients.
27
28
29 328 BMC Med Res Methodol 2011 May 28;11:83.
30
31
32 329 (32) Greenland S. The effect of misclassification in the presence of covariates. Am J Epidemiol 1980
33
34 330 Oct;112(4):564-569.
35
36
37
38 331 (33) Moller S, Jensen MB, Ejertsen B, et al. The clinical database and the treatment guidelines of the Danish
39
40 332 Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol
41
42 333 2008;47(4):506-524.
43
44
45
46 334 (34) Caine GJ, Stonelake PS, Rea D, et al. Coagulopathic complications in breast cancer. Cancer 2003 Oct
47
48 335 15;98(8):1578-1586.
49
50
51
52 336
53
54
55 337
56
57
58
59
60

Table 1. Characteristics of the breast cancer and the matched comparison cohorts, 1994–2010.

	Breast cancer cohort		Comparison cohort	
	Women, N	(%)	Women, N	(%)
Number of patients				
0–1 year of follow-up	62,376		304,803	
2–5 years of follow-up	57,857		296,326	
Age group in years				
0–59	27,013	(43)	134,598	(44)
60–69	17,065	(27)	81,640	(27)
70–79	10,846	(17)	53,000	(17)
≥80	7,452	(12)	35,565	(12)
Year of cancer diagnosis/index date^a				
1995–1999	16,949	(27)	83,263	(27)
2000–2004	18,894	(30)	92,488	(30)
2005–2010	26,533	(43)	129,052	(42)
Cancer stage				
Local	28,936	(46)	N/A	
Regional	24,210	(39)	N/A	
Distant	3,302	(5.3)	N/A	
Unknown	5,928	(9.5)	N/A	
Charlson Comorbidity Index score				
0	46,856	(75)	231,713	(76)
1	8,037	(13)	38,854	(13)
2–3	6,437	(10)	30,419	(10)
≥4	1,047	(1.7)	3,817	(1.3)
Individual comorbidities in the Charlson Comorbidity Index				
Myocardial infarction	1,086	(1.7)	4,909	(1.6)
Congestive heart failure	1,258	(2.0)	5,333	(1.7)
Peripheral vascular disease	1,267	(2.0)	5,598	(1.8)
Cerebrovascular disease	2,919	(4.7)	13,530	(4.4)
Dementia	426	(0.7)	1,888	(0.6)
Chronic pulmonary disease	3,118	(5.0)	14,446	(4.7)
Connective tissue disease	1,471	(2.4)	6,766	(2.2)
Ulcer disease	1,623	(2.6)	7,509	(2.5)
Mild liver disease	402	(0.6)	1,764	(0.6)
Diabetes I and II	1,751	(2.8)	7,837	(2.6)
Hemiplegia	87	(0.1)	365	(0.1)
Moderate to severe renal disease	445	(0.7)	1,892	(0.6)
Diabetes with end-organ damage	653	(1.0)	2,832	(0.9)
Any tumor ^b	3,221	(5.2)	15,196	(5.0)
Leukemia	66	(0.1)	273	(0.1)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Lymphoma	189	(0.3)	859	(0.3)
Moderate to severe liver disease	77	(0.1)	311	(0.1)
Metastatic solid tumor	296	(0.5)	1,320	(0.4)
AIDS	6	(0)	30	(0)
Other comorbidities				
Atrial fibrillation	567	(0.9)	2,453	(0.8)
Obesity	1,330	(2.1)	5,984	(2.0)
Cases of VTE^c				
0–1 year of follow-up				
DVT	195	(39)	309	(46)
PE	178	(35)	235	(35)
Other VTEs	129	(26)	124	(19)
2–5 years of follow-up				
DVT	333	(26)	1,025	(34)
PE	289	(22)	827	(28)
Other VTEs	167	(13)	456	(15)

^aDefined as date of breast cancer diagnosis for the breast cancer cohort and date of sampling for the matched cohort.

^bExcluding breast cancer.

^cPercentages are calculated based on the number of women with VTE.

338

339

340

Table 2. 0–1 year and 2–5 year VTE rate, interaction contrasts (IC), and VTE rate ratio by Charlson Comorbidity Index (CCI) score for the breast cancer and matched comparison cohorts.

0–1 year follow-up

CCI score	Cohort	Number of VTEs	Person-years	Rate (95% CI)	IC (95% CI)	VTE rate ratio (95% CI)
0	Breast	324	45,342	7.1 (6.4, 7.9)	Ref	4.8 (4.1, 5.6)
0	Comparison	346	229,978	1.5 (1.4, 1.7)		
1	Breast	93	7,543	12 (10, 15)	3.2 (0.5, 5.9)	3.5 (2.7, 4.6)
1	Comparison	134	37,966	3.5 (3.0, 4.2)		
2–3	Breast	70	5,936	12 (9.2, 15)	1.2 (-1.8, 4.2)	2.4 (1.8, 3.1)
2–3	Comparison	146	29,201	5.0 (4.2, 5.8)		
≥4	Breast	15	910	17 (9.2, 26)	-1.3 (-11, 7.9)	1.3 (0.7, 2.4)
≥4	Comparison	42	3,455	12 (8.8, 16)		

2–5 year follow-up

CCI score	Cohort	Number of VTEs	Person-years	Std. Rate (95%CI)	IC (95%CI)	VTE rate ratio (95% CI)
0	Breast	533	135,618	4.3 (3.9, 4.6)	Ref	2.2 (2.0, 2.4)
0	Comparison	1384	747,209	2.1 (2.0, 2.2)		
1	Breast	136	19,861	6.4 (5.3, 7.6)	0.9 (-0.4, 2.1)	1.7 (1.4, 2.1)
1	Comparison	436	109,138	3.4 (3.0, 3.7)		
2–3	Breast	100	14,766	6.1 (4.7, 7.5)	-0.5 (-2.1, 1.0)	1.2 (1.0, 1.6)
2–3	Comparison	433	79,310	4.5 (4.0, 5.0)		
≥4	Breast	20	1,834	10 (3.9, 17)	2.3 (-4.3, 8.9)	1.5 (0.9, 2.5)
≥4	Comparison	55	7,825	5.8 (4.0, 7.5)		

1
2
3
4 342
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10 1 **Title: Impact of comorbidity on risk of venous thromboembolism in breast cancer patients – A Danish**
11
12 2 **population-based cohort study**

13
14 3 **Authors and affiliations**

15 4 Anne Gulbech Ording¹

16 5 Erzsébet Horváth-Puhó¹

17 6 Jens Peter Garne²

18 7 Petra Witt Nyström³

19 8 Mogens Vyberg⁴

20 9 Henrik Toft Sørensen¹

21 10 Timothy L. Lash^{1,5}

22 11 ¹Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

23 12 ²Breast Clinic, Aalborg University Hospital, Aalborg, Denmark

24 13 ³Department of Oncology, Uppsala University Hospital, Uppsala, Sweden

25 14 ⁴Institute of Pathology, Aalborg University Hospital, Aalborg, Denmark

26 15 ⁵Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA

27 16 **Corresponding author**

28 17 Anne G. Ording, Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200

29 18 Aarhus N. E-mail address: ao@dce.au.dk; Telephone: +45 87 16 80 63; Fax: +45 87 16 72 15

30 19
31 20 **Running title:** Breast cancer, comorbidity and risk of VTE

32 21 **Key words:** Breast neoplasms, comorbidity, morbidity, venous thrombosis, haemostasis, epidemiology

33 22 **Abstract word count:** **218219**, **manuscript word count:** **2,1562,472**.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: To assess the interaction between comorbidity and breast cancer (BC) on the rate of venous thromboembolism (VTE) beyond what can be explained by the independent effects of BC and comorbidity.

Design: Population-based matched cohort study.


Setting: Denmark.

Participants: Danish BC patients (n=62,376) diagnosed 1995–2010 and a comparison cohort of women without BC (n=304,803) from the general population matched to the BC patients on year of birth in five-year intervals and on the specific diseases included in the Charlson Comorbidity Index (CCI) and atrial fibrillation and obesity.

Measures: The rate ratios of VTE per 1000 person-years (PYS) were computed by comorbidity levels using the CCI, and interaction contrasts (IC) were calculated as a measure of the excess or deficit VTE rate not explained by the independent effects of BC and comorbidity.

Results: Among BC patients with a CCI score of 1, the 0-1 year VTE rate was 12 per 1000 person-years (PYS), and interaction accounted for 10% of the rate (IC= 3.2, 95% confidence interval (CI), 0.5, 5.9). Among BC patients with CCI ≥4, the VTE rate was 17, and interaction accounted for 8% of the rate (IC= 1.2, 95%CI, -1.8, 4.2). There was no interaction during 2–5 years of follow-up.

Conclusion: There was only little interaction between BC and the CCI score on the rate of VTE.



Article summary

- The study included all Danish breast cancer patients diagnosed 1995–2010 and a comparison cohort of women from the general population free of breast cancer. The study had complete follow-up on all participants from the nationwide Danish Civil Registration System.
- The study was conducted in a government financed health care system with equal access for the entire Danish population.
- The validity of the Danish National Registry of Patients as a source of information on comorbidity and VTE has varying completeness and validity for different diseases.
- The CCI as a measure of the combined burden of comorbidity does not allow for estimation of disease severity and duration.

Background

Venous thromboembolism (VTE), i.e., deep venous thrombosis (DVT) and pulmonary embolism (PE), is associated with high morbidity and mortality, in particular during hospitalization.¹ Cancer and VTE are strongly related and VTE can be a marker of occult cancer as well as a serious complication of cancer.² Cancer-associated VTE risk is up to seven times higher compared to that of the general population,³⁻⁵ and the rate is mainly increased during the first year following cancer diagnosis.^{3,6} Important risk

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

factors include cancer type and cancer stage, but may also be related to treatment including chemotherapy and central venous catheters used for treatment administration.^{1,7,8}

Breast cancer is the most common cancer among women in most of the developed world,⁹ and an estimated 20% of patients are burdened with major comorbid conditions at diagnosis.¹⁰ While there is evidence for a link between some diseases, such as stroke, heart failure, and osteoporosis, and risk of VTE,¹¹⁻¹⁴ it is largely unknown how chronic diseases in breast cancer affect the risk of VTE compared to the general population free of breast cancer.

To our knowledge, no studies have compared the risk of VTE among BC patients to a comparison cohort of women free of BC [from the general population](#) and accounted for comorbidity. We computed the interaction contrast (IC) as a measure of interaction between breast cancer and comorbidity levels using the Charlson Comorbidity Index (CCI) as a measure of comorbidity.¹⁵ The IC is an estimate of the VTE rate that cannot be explained by the effects of breast cancer or comorbidity acting alone.¹⁶

Field Code Changed

Formatted: English (U.S.)

BMJ Open: first published as 10.1136/bmjopen-2014-005082 on 5 June 2014. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10 **73 Methods**

11
12 *74 Design and setting*

13
14 *75* To compare VTE rates in a cohort of breast cancer patients with corresponding rates in a cohort of
15
16 *76* women free of breast cancer, we designed a nationwide cohort study including all patients
17
18 *77* diagnosed with breast cancer in Denmark between 1995 and 2010 and a comparison cohort of
19
20 *78* women selected from the general population. Women in the comparison cohort were matched to
21
22 *79* each breast cancer patient on year of birth in five-year intervals and on the specific diseases
23
24 *80* included in the CCI, and on history of atrial fibrillation and obesity, as atrial fibrillation is treated
25
26 *81* with anticoagulation and obesity is a risk factor for VTE.^{15,17,18}

27
28
29 *82* The study used administrative and medical registries in Denmark, where the national health care
30
31 *83* system provides tax-supported access to primary care and hospitals for all legal residents.¹⁹ The
32
33 *84* Civil Registration System (CRS) maintains up-to-date information on vital and civil status for all
34
35 *85* Danish residents.²⁰ Since 1968, all residents of Denmark have been assigned a Civil Personal
36
37 *86* Registration (CPR) number, which facilitates accurate linkage between medical registries. This
38
39 *87* study made use of such registries to provide information on breast cancer and other hospital
40
41 *88* diagnoses (see appendix).

42
43
44 *89 Ascertainment of the breast cancer and comparison cohorts*

45 *90* The Danish Cancer Registry (DCR) was established in 1943 and records all cancers diagnosed in
46
47 *91* Denmark.^{21,22} We identified all female breast cancer patients diagnosed between 1995 and 2010 and
48
49 *92* excluded patients with a VTE diagnosis preceding the index (diagnosis) date. For women in the
50

1
2
3
4
5
6
7
8
9
10 93 comparison cohort, the index date was defined as the date of breast cancer diagnosis for the matched
11
12 94 case.

13
14 95 From the CRS, we selected up to five women from the general population and matched them without
15
16 96 replacement to each breast cancer patient on age (5-year intervals) and on hospital history of specific
17
18 97 comorbidities included in the CCI,¹⁵ and on presence/absence of atrial fibrillation and obesity. [We](#)
19
20 98 [were unable to find matched comparison women to 428 breast cancer patients due to high age and](#)
21
22 99 [many comorbidities, which precluded matching.](#) Women in the comparison cohort could not have
23
24 100 previous diagnostic codes for breast cancer or VTE as of the date of breast cancer diagnosis for the
25
26 101 corresponding case [but were eligible for inclusion in the breast cancer cohort if they developed breast](#)
27
28 102 [cancer.](#)

31 32 104 *Comorbidity*

33
34 105 The Danish National Registry of Patients (DNRP) contains information on all non-psychiatric discharge
35
36 106 diagnoses for inpatient hospitalizations since 1977. Information on visits to outpatient specialist and
37
38 107 emergency departments was added from 1995. The DNRP records diagnoses and dates of hospital
39
40 108 contacts.²³ This registry was used to identify all diagnoses of diseases included in the CCI,¹⁵ as well as
41
42 109 atrial fibrillation and obesity, for members of the two cohorts (see Appendix). Atrial fibrillation and
43
44 110 obesity were included in the CCI with a weight of one.

45 46 111 47 48 112 *Venous thromboembolism*

49
50 113 The study outcome was VTE, defined as any in- or outpatient discharge diagnosis of PE, DVT, or other
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10 VTE diagnosed after the index date (see Appendix), [thereby excluding VTE that was only diagnosed at](#)
11 [emergency departments due to a low positive predictive value](#).²⁴ Because of the little impact on
12
13 mortality risk associated with DVT alone, patients coded as having both DVT and PE on their first
14
15 diagnosis date were classified as PE patients.
16
17
18
19

20 *Follow-up*

21
22 The breast cancer and comparison cohorts were followed from the index date until the first
23
24 occurrence of VTE, death, emigration or five years of follow-up, whichever came first. If a matched
25
26 comparison cohort member received a breast cancer diagnosis, follow-up was censored and the
27
28 woman was switched to the breast cancer cohort. The person-time was divided into two survivor
29
30 cohorts, the first with one year of follow-up and the second with [twomore than one](#) to five years of
31
32 follow-up.
33
34
35

36 *Statistical analysis*

37
38 First, we computed proportions of women in the breast cancer cohort and the matched comparison
39
40 cohort within categories of age (0–59, 60–69, 70–79, and ≥80 years), index year (1995–1999, 2000–
41
42 2004, and 2005–2010), baseline CCI score (0, 1, 2–3, ≥4), individual CCI comorbidities,
43
44 presence/absence of atrial fibrillation and obesity, and—for the breast cancer cohort—breast cancer
45
46 stage at diagnosis (local, regional, distant, or unknown).
47

48 Next, [we computed cumulative incidence estimates for VTE, which takes into account the competing](#)
49 [risk of death \(an event that, precludes subsequent VTE occurrence\)](#).²⁵
50
51
52
53
54
55
56
57
58
59
60

Formatted: English (U.S.)

1
2
3
4
5
6
7
8
9
10¹³⁵ We then computed the rate of VTE within the categories described above for the two cohorts and
11
12¹³⁶ created Cox proportional hazard regression models to compute the hazard ratios (HRs) [as a measure](#)
13
14¹³⁷ [of the VTE rate ratio](#) adjusted for age (continuous) and year of breast cancer diagnosis (1995–1999 vs.
15
16¹³⁸ 2005–2010, 2000–2004 vs. 2005–2010) to compute rate ratios for VTE within strata of comorbidity.
17
18¹³⁹ As comorbid conditions were matched factors, the matching had to be dissolved in all adjusted
19
20¹⁴⁰ analyses and for analyses of the [2–5](#) year survival cohort. To account for changes in the age
21
22¹⁴¹ distribution at one year of follow-up, VTE rates for the [2–5](#) year survivor cohort were standardized
23
24¹⁴² to the age distribution of the breast cancer patients as of their index dates. [The proportionality](#)
25
26¹⁴³ [assumption in Cox models were examined with log minus log plots, and both this and the linearity](#)
27
28¹⁴⁴ [assumption of the effect of age were found to be acceptable.](#) The interaction between breast cancer
29
30¹⁴⁵ and comorbidity on the rate of VTE was examined by calculating the IC, which measures the excess or
31
32¹⁴⁶ deficit rate of VTE above or below that expected given the baseline VTE rate, the effect of breast
33
34¹⁴⁷ cancer on the VTE rate, and the effect of comorbidity on the VTE rate, [based on additivity of effects.](#) It
35
36¹⁴⁸ is calculated as the difference between the rate differences (VTE rate in the breast cancer cohort
37
38¹⁴⁹ minus the VTE rate in the comparison cohort) in the strata with and without comorbidity.¹⁶ [The IC is a](#)
39
40¹⁵⁰ [measure of the synergistic or antagonistic interaction between two factors that cannot be explained](#)
41
42¹⁵¹ [by their individual effects.](#)
43
44¹⁵² Analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, NC).
45
46¹⁵³ The study was approved by the Danish Data Protection Agency (2011-41-6174).

47 48¹⁵⁴ 49¹⁵⁵ **Results**

1
2
3
4
5
6
7
8
9
10¹⁵⁶ Descriptive statistics of the cohorts are shown in Table 1. The study included 62,376 breast cancer
11
12¹⁵⁷ patients and 304,803 women from the general population matched to the breast cancer patients
13
14¹⁵⁸ diagnosed between 1995 and 2010. The median age in the breast cancer cohort was 62.3 years
15
16¹⁵⁹ (inter-quartile range (IQR), 52.8, 72.3), [and 62.0 \(IQR: 52.6, 72.9\) in the comparison cohort, and in the](#)
17
18¹⁶⁰ [breast cancer and comparison cohort, 75% and 76% of all women](#) ~~the cohort members~~ had a CCI score
19
20¹⁶¹ of 0 at the ~~index date~~ [time of breast cancer diagnosis](#). During the first year of follow-up, there were
21
22¹⁶² 502 [\(0.8%\)](#) and 668 [\(0.2%\)](#) cases of VTE in the breast cancer and the matched comparison cohort,
23
24¹⁶³ respectively, of which 39% vs. 46% were DVT, 35% were PE in both cohorts, and 26% vs. 19% were
25
26¹⁶⁴ other VTEs, respectively. By five years of follow-up, an additional 789 [\(1.4%\)](#) cases of VTE were
27
28¹⁶⁵ diagnosed in the breast cancer cohort and 2,308 [\(0.8%\)](#) in the comparison cohort.

29
30
31¹⁶⁶ Table 2 presents the VTE rates, ICs, and adjusted VTE rate ratios for 0–1 year and ~~2–5~~ 5 years of
32
33¹⁶⁷ follow-up in the breast cancer and comparison cohorts. After taking into account death as a
34
35¹⁶⁸ competing risk, the breast cancer cohort was at higher risk for all types of VTE within 1 year of follow-
36
37¹⁶⁹ up [\(0.80%, 95%CI: 0.74, 0.88\) and 0.22% \(95%CI: 0.20, 0.24\), respectively](#) and at 5 years of follow-up
38
39¹⁷⁰ [\(1.6%, 95%CI: 1.50, 1.73\) and 0.93% \(95%CI: 0.90, 0.97, respectively\)](#). At one year of follow-up, the
40
41¹⁷¹ VTE rate was 8.4 (95% confidence interval (CI), 7.7, 9.2) per 1000 person-years (PY) in the breast
42
43¹⁷² cancer cohort and 2.2 (95% CI, 2.1, 2.4) per 1000 PY in the comparison cohort (data not shown). In all
44
45¹⁷³ strata of CCI scores, the breast cancer cohort had higher rates of VTE compared to the comparison
46
47¹⁷⁴ cohort, but the corresponding hazard ratios (HRs) decreased with increasing CCI score. The HR for VTE
48
49¹⁷⁵ was 4.8 (95%CI, 4.1, 5.6) for a CCI score of 0, and 1.3 (95%CI, 0.7, 2.4) for a CCI score of ≥ 4 . During
50
51¹⁷⁶ ~~2–5~~ 5 years of follow-up, the corresponding HRs were 2.2 (95%CI, 2.0, 2.4) for a CCI score of 0 and 1.5

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(95%CI, 0.9, 2.5) for a CCI score of ≥ 4 .

The IC analysis revealed a small amount of interaction between breast cancer and the CCI score, which weakened with increasing CCI score, suggesting that the combined effect of breast cancer and comorbidity mainly impacts the VTE rates in presence of low comorbidity levels. Interaction accounted for 3.2 (95%CI, 0.5, 5.9) cases of VTE per 1000 PY for a CCI score of 1, 1.2 (95%CI, -1.8, 4.2) cases of VTE for a CCI score of 2-3, and -1.3 (95%CI, -11, 7.9) cases of VTE for a CCI score of ≥ 4 per 1000 PY, representing 27%, 10%, and -7.6% of total VTE rates, respectively. During 2-5 years of follow-up weak interaction was only observed for a CCI score of ≥ 4 (IC, 2.3, 95%CI, -4.3, 8.9/1000PY), corresponding to 23% of the total VTE rate.

Discussion

In this nationwide study, the breast cancer cohort had elevated rates of VTE compared to women from the comparison cohort in all categories of comorbidity. However, comparing the breast cancer cohort to the comparison cohort within levels of the CCI score, VTE rate differences remained nearly constant as the comorbidity level increased, whereas the rate ratios declined with increasing CCI score. We found that there was only a small amount of interaction between breast cancer and the CCI score on the VTE rate, which primarily was observed during the first year after breast cancer diagnosis for patients with a CCI score of 1. This pattern of effects and interactions suggests that comorbidity and breast cancer or its treatment effect the rate of VTE for breast cancer patients with a CCI score of

1 and in the first year of follow-up. [Previous studies have found that BC does not confer a large increased risk of VTE compared to many other cancer types,³ which may provide one explanation for](#)

Formatted: Not Highlight
Formatted: Not Highlight

1
2
3
4
5
6
7
8
9
10¹⁹⁷ [the relatively small amount of interaction in BC patients compared to women from the general](#)
11 [population.](#)

12¹⁹⁸
13
14
15¹⁹⁹ [Interaction contrasts were negative in some analyses, although often imprecisely measured. Negative](#)
16 [interaction contrasts suggest that the joint effect of breast cancer and comorbidity is less than](#)
17²⁰⁰ [expected from their individual effects.](#) In women with multiple comorbidities, and at longer times of
18
19²⁰¹
20
21²⁰² follow-up, the independent effects of comorbidity and breast cancer, therefore, dominate the overall
22
23²⁰³ risk of VTE, possibly due to the higher baseline risk of VTE contributed by each of these factors.
24
25²⁰⁴

26
27²⁰⁵ In our study, breast cancer patients had higher VTE rates than the comparison cohort women in all
28
29²⁰⁶ strata of comorbidity, particularly in the first year of follow-up. Such an effect is probably due to a
30
31²⁰⁷ prothrombotic state associated with the cancer and cancer-directed treatments such as surgery,
32
33²⁰⁸ chemotherapy, and antihormonal therapies.^{14,26,27} Other medications used to treat cancer symptoms
34
35²⁰⁹ and comorbid conditions, such as NSAIDs and glucocorticoids, could elevate VTE risk.^{28,29} With
36
37²¹⁰ increasing CCI score, the rates of VTE in the two cohorts approached each other. This finding may be
38
39²¹¹ explained by a potential greater effect of the cumulative comorbidity burden on the VTE risk, while
40
41²¹² the effect of breast cancer remains similar within each strata of comorbidity.

42²¹³ Therefore the presence of comorbidity may be a factor worth considering in future prediction models.
43
44

45²¹⁴ This study was based on a nationwide cohort of breast cancer patients, and we achieved [almost](#)
46
47²¹⁵ complete follow-up through the CRS, limiting selection bias.

48
49²¹⁶ Despite these strengths, there are several study limitations to consider. [Data on breast cancer](#)
50
51²¹⁷ [obtained from the DCR are virtually complete.](#)³⁰ The positive predictive values for the CCI diseases

Formatted: Font: 12 pt, Not Italic, Font color: Blue

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

recorded in the DNRP are above 80% high compared to medical record review.³¹ However, outpatient data were not registered before 1995, and the impact of any resulting misclassification of comorbidities on estimates of the interaction contrast are unclear.³² The definition of VTE included both in- and outpatient discharge VTE diagnoses, but the accuracy of these diagnoses vary for type of diagnosis and hospital department, with the highest PPV of 75% for inpatient diagnoses.²⁴ To reduce the number of invalid VTE diagnoses, we only included inpatient and outpatient VTE diagnoses thereby disregarding VTE only diagnosed at emergency departments, which have poor predictive value.²⁴ Any bias resulting from the potential rate of misclassification could be affected by a diagnosis of breast cancer and lead to surveillance bias, because patients receive thorough medical care, particularly in the initial years following diagnosis.³³ With increasing CCI score, the VTE rates among the breast cancer patients approach the rates of comparison women, suggesting that the amount of medical surveillance is more similar between the cohorts with increasing morbidity. In addition, intravenous catheters used in connection with cancer surgery or chemotherapy are linked to VTE.³⁴ Such associations could affect the accuracy of DVT diagnoses. Furthermore, we lacked information on several important factors, for example cancer treatment, abnormal laboratory findings, use of hormone replacement therapy, other medications, and intravenous catheters, which could independently affect VTE risk.

In summary, we found only little interaction between breast cancer and the CCI score on the rate of VTE. While there was little interaction, it does appear that patients and physicians should consider comorbidities when contemplating prophylactic anticoagulation for breast cancer patients.

Formatted: English (U.S.)

Formatted: Font: 12 pt

1
2
3
4
5
6
7
8
9
10 **References**

- 11
12²³⁹ (1) Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of
13
14²⁴⁰ thromboprophylaxis. *Cancer* 2011 Apr 1;117(7):1334-1349.
15
16
17²⁴¹ (2) Sorensen HT, Mellekjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous
18
19²⁴² thromboembolism. *N Engl J Med* 2000 Dec 21;343(25):1846-1850.
20
21²⁴³ (3) Cronin-Fenton DP, Sondergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, et al. Hospitalisation for
22
23²⁴⁴ venous thromboembolism in cancer patients and the general population: a population-based cohort study in
24
25²⁴⁵ Denmark, 1997-2006. *Br J Cancer* 2010 Sep 28;103(7):947-953.
26
27
28²⁴⁶ (4) Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ,3rd. Risk factors for deep vein
29
30²⁴⁷ thrombosis and pulmonary embolism: a population-based case-control study. *Arch Intern Med* 2000 Mar
31²⁴⁸ 27;160(6):809-815.
32
33
34²⁴⁹ (5) Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of
35
36²⁵⁰ venous thrombosis. *JAMA* 2005 Feb 9;293(6):715-722.
37
38
39²⁵¹ (6) Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on
40
41²⁵² survival in breast cancer patients. *J Clin Oncol* 2007 Jan 1;25(1):70-76.
42
43²⁵³ (7) Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous
44
45²⁵⁴ thromboembolism among hospitalized cancer patients. *Cancer* 2007 Nov 15;110(10):2339-2346.
46
47
48²⁵⁵ (8) Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in
49
50²⁵⁶ cancer patients. *J Clin Oncol* 2003 Oct 1;21(19):3665-3675.
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- (9) Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010 Dec 15;127(12):2893-2917.
- (10) Cronin-Fenton DP, Norgaard M, Jacobsen J, Garne JP, Ewertz M, Lash TL, et al. Comorbidity and survival of Danish breast cancer patients from 1995 to 2005. *Br J Cancer* 2007 May 7;96(9):1462-1468.
- (11) Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. *Am J Epidemiol* 2005 Nov 15;162(10):975-982.
- (12) Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW, et al. An association between atherosclerosis and venous thrombosis. *N Engl J Med* 2003 Apr 10;348(15):1435-1441.
- (13) Breart G, Cooper C, Meyer O, Speirs C, Deltour N, Reginster JY. Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database. *Osteoporos Int* 2010 Jul;21(7):1181-1187.
- (14) Anderson FA, Jr, Spencer FA. Risk factors for venous thromboembolism. *Circulation* 2003 Jun 17;107(23 Suppl 1):I9-16.
- (15) Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40(5):373-383.
- (16) Rothman KJ, Greenland S, Lash TL. Concepts of Interaction. *Modern Epidemiology*. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 71-86.

- 1
2
3
4
5
6
7
8
9
10 274 (17) Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and
11
12 275 venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern
13
14 276 Med 2002 May 27;162(10):1182-1189.
15
16
17 277 (18) Lip GY, Tse HF. Management of atrial fibrillation. Lancet 2007 Aug 18;370(9587):604-618.
18
19 278 (19) Frank L. Epidemiology. When an entire country is a cohort. Science 2000 Mar 31;287(5462):2398-2399.
20
21
22 279 (20) Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight
23
24 280 million persons. Dan Med Bull 2006 Nov;53(4):441-449.
25
26
27 281 (21) Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry--history, content, quality and
28 282 use. Dan Med Bull 1997 Nov;44(5):535-539.
29
30
31 283 (22) Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health 2011 Jul;39(7 Suppl):42-45.
32
33
34 284 (23) Andersen TF, Madsen M, Jorgensen J, Mellekjoer L, Olsen JH. The Danish National Hospital Register. A
35
36 285 valuable source of data for modern health sciences. Dan Med Bull 1999 Jun;46(3):263-268.
37
38 286 (24) Severinsen MT, Kristensen SR, Overvad K, Dethlefsen C, Tjonneland A, Johnsen SP. Venous
39
40 287 thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution. J
41
42 288 Clin Epidemiol 2010 Feb;63(2):223-228.
43
44
45 289 (25) Andersen PK, Geskus RB, de Witte T, Putter H. Competing risks in epidemiology: possibilities and pitfalls.
46 290 Int J Epidemiol 2012 Jun;41(3):861-870.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(26) Mandala M, Barni S, Prins M, Labianca R, Tondini C, Russo L, et al. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. *Ann Oncol* 2010 Apr;21(4):871-876.

(27) Degen JL, Palumbo JS. Hemostatic factors, innate immunity and malignancy. *Thromb Res* 2012 Apr;129 Suppl 1:S1-5.

(28) Johannesdottir SA, Horvath-Puho E, Dekkers OM, Cannegieter SC, Jorgensen JO, Ehrenstein V, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. *JAMA Intern Med* 2013 May 13;173(9):743-752.

(29) Schmidt M, Christiansen CF, Horvath-Puho E, Glynn RJ, Rothman KJ, Sorensen HT. Non-steroidal anti-inflammatory drug use and risk of venous thromboembolism. *J Thromb Haemost* 2011 Jul;9(7):1326-1333.

(30) Jensen AR, Overgaard J, Storm HH. Validity of breast cancer in the Danish Cancer Registry. A study based on clinical records from one county in Denmark. *Eur J Cancer Prev* 2002 Aug;11(4):359-364.

(31) Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. *BMC Med Res Methodol* 2011 May 28;11:83.

(32) Greenland S. The effect of misclassification in the presence of covariates. *Am J Epidemiol* 1980 Oct;112(4):564-569.

(33) Moller S, Jensen MB, Ejlersen B, Bjerre KD, Larsen M, Hansen HB, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. *Acta Oncol* 2008;47(4):506-524.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

³¹¹ (34) Caine GJ, Stonelake PS, Rea D, Lip GY. Coagulopathic complications in breast cancer. *Cancer* 2003 Oct
³¹² 15;98(8):1578-1586.

For peer review only




Table 1. Characteristics of the breast cancer and [the matched](#) comparison cohorts, [1994–2010](#).

	Breast cancer cohort		Matched comparison cohort	
	Women, N	(%)	Women, N	(%)
Number of patients				
0–1 year of follow-up	62,376		304,803	
≥1–5 years of follow-up	57,857		296,326	
Age group in years				
0–59	27,013	(43)	134,598	(44)
60–69	17,065	(27)	81,640	(27)
70–79	10,846	(17)	53,000	(17)
≥80	7,452	(12)	35,565	(12)
Year of cancer diagnosis/index date^a				
1995–1999	16,949	(27)	83,263	(27)
2000–2004	18,894	(30)	92,488	(30)
2005–2010	26,533	(43)	129,052	(42)
Cancer stage				
Local	28,936	(46)	N/A	
Regional	24,210	(39)	N/A	
Distant	3,302	(5.3)	N/A	
Unknown	5,928	(9.5)	N/A	
Charlson Comorbidity Index score				
0	46,856	(75)	231,713	(76)
1	8,037	(13)	38,854	(13)
2–3	6,437	(10)	30,419	(10)
≥4	1,047	(1.7)	3,817	(1.3)
Individual comorbidities in the Charlson Comorbidity Index				
Myocardial infarction	1,086	(1.7)	4,909	(1.6)
Congestive heart failure	1,258	(2.0)	5,333	(1.7)
Peripheral vascular disease	1,267	(2.0)	5,598	(1.8)
Cerebrovascular disease	2,919	(4.7)	13,530	(4.4)
Dementia	426	(0.7)	1,888	(0.6)
Chronic pulmonary disease	3,118	(5.0)	14,446	(4.7)
Connective tissue disease	1,471	(2.4)	6,766	(2.2)
Ulcer disease	1,623	(2.6)	7,509	(2.5)
Mild liver disease	402	(0.6)	1,764	(0.6)
Diabetes I and II	1,751	(2.8)	7,837	(2.6)
Hemiplegia	87	(0.1)	365	(0.1)
Moderate to severe renal disease	445	(0.7)	1,892	(0.6)
Diabetes with end-organ damage	653	(1.0)	2,832	(0.9)
Any tumor ^b	3,221	(5.2)	15,196	(5.0)

10	Leukemia	66	(0.1)	273	(0.1)
11	Lymphoma	189	(0.3)	859	(0.3)
12	Moderate to severe liver disease	77	(0.1)	311	(0.1)
13	Metastatic solid tumor	296	(0.5)	1,320	(0.4)
14	AIDS	6	(0)	30	(0)
15	Other comorbidities				
16	Atrial fibrillation	567	(0.9)	2,453	(0.8)
17	Obesity	1,330	(2.1)	5,984	(2.0)
18	Cases of VTE^c				
19	0–1 year of follow-up				
20	DVT	195	(39)	309	(46)
21	PE	178	(35)	235	(35)
22	Other VTEs	129	(26)	124	(19)
23	≥1–5 years of follow-up				
24	DVT	333	(26)	1,025	(34)
25	PE	289	(22)	827	(28)
26	Other VTEs	167	(13)	456	(15)

^aDefined as date of breast cancer diagnosis for the breast cancer cohort and date of sampling for the matched cohort.

^bExcluding breast cancer.

^cPercentages are calculated based on the number of women with VTE.

Table 2. 0–1 year and ≥ 1 –5 year VTE rate, interaction contrasts (IC), and VTE rate ratio by Charlson Comorbidity Index (CCI) score for the breast cancer and matched comparison cohorts.

0–1 year follow-up

CCI score	Cohort	Number of VTEs	Person-years	Rate (95% CI)	IC (95% CI)	VTE rate ratio ^{HR} (95% CI)
0	Breast	324	45,342	7.1 (6.4, 7.9)	Ref	4.8 (4.1, 5.6)
0	Comparison	346	229,978	1.5 (1.4, 1.7)		
1	Breast	93	7,543	12 (10, 15)	3.2 (0.5, 5.9)	3.5 (2.7, 4.6)
1	Comparison	134	37,966	3.5 (3.0, 4.2)		
2–3	Breast	70	5,936	12 (9.2, 15)	1.2 (-1.8, 4.2)	2.4 (1.8, 3.1)
2–3	Comparison	146	29,201	5.0 (4.2, 5.8)		
≥ 4	Breast	15	910	17 (9.2, 26)	-1.3 (-11, 7.9)	1.3 (0.7, 2.4)
≥ 4	Comparison	42	3,455	12 (8.8, 16)		

≥ 1 –5 year follow-up

CCI score	Cohort	Number of VTEs	Person-years	Std. Rate (95%CI)	IC (95%CI)	VTE rate ratio ^{HR} (95% CI)
0	Breast	533	135,618	4.3 (3.9, 4.6)	Ref	2.2 (2.0, 2.4)
0	Comparison	1384	747,209	2.1 (2.0, 2.2)		
1	Breast	136	19,861	6.4 (5.3, 7.6)	0.9 (-0.4, 2.1)	1.7 (1.4, 2.1)
1	Comparison	436	109,138	3.4 (3.0, 3.7)		
2–3	Breast	100	14,766	6.1 (4.7, 7.5)	-0.5 (-2.1, 1.0)	1.2 (1.0, 1.6)
2–3	Comparison	433	79,310	4.5 (4.0, 5.0)		
≥ 4	Breast	20	1,834	10 (3.9, 17)	2.3 (-4.3, 8.9)	1.5 (0.9, 2.5)
≥ 4	Comparison	55	7,825	5.8 (4.0, 7.5)		

Appendix. ICD-codes identifying breast cancer, VTE, and comorbidities.

ICD codes	ICD-8	ICD-10
Breast cancer	174	C50
Pulmonary embolism	45099	I26
Deep venous thrombosis	45100	I801, I802, I803
Other VTEs	45101, 45108, 45109, 45190, 45191, 45192, 45199, 45299, 453	I800, I808, I809, I81, I82
Myocardial infarction	410	I21, I22, I23
Congestive heart failure	427.09, 427.10, 427.11, 427.19, 428.99, 782.49	I50, I11.0, I13.0, I13.2
Peripheral vascular disease	440, 441, 442, 443, 444, 445	I70, I71, I72, I73, I74, I77
Cerebrovascular disease	430-438	I60-I69, G45, G46
Dementia	290.09-290.19, 293.09	F00-F03, F05.1, G30
Chronic pulmonary disease	490-493, 515-518	J40-J47, J60-J67, J68.4, J70.1, J70.3, J84.1, J92.0, J96.1, J98.2, J98.3
Connective tissue disease	712, 716, 734, 446, 135.99	M05, M06, M08, M09, M30, M31, M32, M33, M34, M35, M36, D86
Ulcer disease	530.91, 530.98, 531- 534	K22.1, K25-K28
Mild liver disease	571, 573.01, 573.04	B18, K70.0-K70.3, K70.9, K71, K73, K74, K76.0
Diabetes type1	249.00, 249.06, 249.07, 249.09	E10.0, E10.1, E10.9
Diabetes type2	250.00, 250.06, 250.07, 250.09	E11.0, E11.1, E11.9
Hemiplegia	344	G81, G82
Moderate to severe renal disease	403, 404, 580- 583, 584, 590.09, 593.19, 753.10- 753.19, 792	I12, I13, N00-N05, N07, N11, N14, N17-N19, Q61
Diabetes with end organ damage Type1	249.01-249.05, 249.08 250.01-250.05, 250.08	E10.2-E10.8

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Type2		E11.2-E11.8
Any tumor, except breast cancer	140-194, except 174	C00-C75, except C50
Leukemia	204-207	C91-C95
Lymphoma	200-203,275.59	C81-C85, C88, C90, C96
Moderate to severe liver disease	070.00, 070.02, 070.04, 070.06, 070.08, 573.00, 456.00-456.09	B15.0, B16.0, B16.2, B19.0, K70.4, K72, K76.6, I85
Metastatic solid tumor	195-198, 199	C76-C80
AIDS	079.83	B21-B24
Atrial fibrillation	42793	I489B
Obesity	27799	E66

Author contributions

AGO, HTS, and TLL conceived and designed the study. AGO, EHP, HTS, TLL acquired, analyzed, and interpreted the data. AGO wrote the first draft and EHP, JPG, PWN, HTS, MV and TLL reviewed, revised, and approved the manuscript.

Funding sources

The study was supported by the Danish Cancer Society (grant no. R73-A4284-13-S17); the Danish Agency for Science, Technology and Innovation (Record number: 10-084581).; Karen Elise Jensen Foundation; Aarhus University Research Foundation; the Clinical Epidemiology Research Foundation, Aarhus University; Aalborg Hospital, Region North Denmark. The funding sources had no role in design, analysis and interpretation of the study.


Conflict of Interest

The Department of Clinical Epidemiology, Aarhus University Hospital, receives funding for other studies from

1
2
3
4
5
6
7
8
9
10³³⁴
11
12³³⁵
13
14
15³³⁶
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

companies in the form of research grants to (and administered by) Aarhus University. None of these studies have any relation to the present study. The authors declare no conflict of interest.

For peer review only



Appendix. ICD-codes identifying breast cancer, VTE, and comorbidities.

ICD codes	ICD-8	ICD-10
Breast cancer	174	C50
Pulmonary embolism	45099	I26
Deep venous thrombosis	45100	I801, I802, I803
Other VTEs	45101, 45108, 45109, 45190, 45191, 45192, 45199, 45299, 453	I800, I808, I809, I81, I82
Myocardial infarction	410	I21, I22, I23
Congestive heart failure	427.09, 427.10, 427.11, 427.19, 428.99, 782.49	I50, I11.0, I13.0, I13.2
Peripheral vascular disease	440, 441, 442, 443, 444, 445	I70, I71, I72, I73, I74, I77
Cerebrovascular disease	430-438	I60-I69, G45, G46
Dementia	290.09-290.19, 293.09	F00-F03, F05.1, G30
Chronic pulmonary disease	490-493, 515-518	J40-J47, J60-J67, J68.4, J70.1, J70.3, J84.1, J92.0, J96.1, J98.2, J98.3
Connective tissue disease	712, 716, 734, 446, 135.99	M05, M06, M08, M09, M30, M31, M32, M33, M34, M35, M36, D86
Ulcer disease	530.91, 530.98, 531- 534	K22.1, K25-K28
Mild liver disease	571, 573.01, 573.04	B18, K70.0-K70.3, K70.9, K71, K73, K74, K76.0
Diabetes type1	249.00, 249.06, 249.07, 249.09	E10.0, E10.1, E10.9
Diabetes type2	250.00, 250.06, 250.07, 250.09	E11.0, E11.1, E11.9
Hemiplegia	344	G81, G82
Moderate to severe renal disease	403, 404, 580- 583, 584, 590.09, 593.19, 753.10- 753.19, 792	I12, I13, N00-N05, N07, N11, N14, N17-N19, Q61
Diabetes with end organ damage		
Type1	249.01-249.05, 249.08 250.01-250.05, 250.08	E10.2-E10.8
Type2		E11.2-E11.8
Any tumor, except breast cancer	140-194, except 174	C00-C75, except C50

Leukemia	204-207	C91-C95
Lymphoma	200-203,275.59	C81-C85, C88, C90, C96
Moderate to severe liver disease	070.00, 070.02, 070.04, 070.06, 070.08, 573.00, 456.00-456.09	B15.0, B16.0, B16.2, B19.0, K70.4, K72, K76.6, I85
Metastatic solid tumor	195-198, 199	C76-C80
AIDS	079.83	B21-B24
Atrial fibrillation	42793	I489B
Obesity	27799	E66

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1, 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5, 6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5, 6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	5, 6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6
Bias	9	Describe any efforts to address potential sources of bias	6, 7
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7, 8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7, 8
		(b) Describe any methods used to examine subgroups and interactions	7, 8
		(c) Explain how missing data were addressed	7, 8
		(d) If applicable, explain how loss to follow-up was addressed	N/A
		(e) Describe any sensitivity analyses	N/A
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	12, 13
		(c) Summarise follow-up time (eg, average and total amount)	14
Outcome data	15*	Report numbers of outcome events or summary measures over time	14
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	14
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	10
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10, 11
Generalisability	21	Discuss the generalisability (external validity) of the study results	11
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16, 17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>